WO2016189109A1 - Polyoxomolybdate-bisphosphonate complex containing a heterometallic ion different from molybdenum - Google Patents
Polyoxomolybdate-bisphosphonate complex containing a heterometallic ion different from molybdenum Download PDFInfo
- Publication number
- WO2016189109A1 WO2016189109A1 PCT/EP2016/061948 EP2016061948W WO2016189109A1 WO 2016189109 A1 WO2016189109 A1 WO 2016189109A1 EP 2016061948 W EP2016061948 W EP 2016061948W WO 2016189109 A1 WO2016189109 A1 WO 2016189109A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- bisphosphonate
- group
- polyoxomolybdate
- zol
- Prior art date
Links
- 229940122361 Bisphosphonate Drugs 0.000 title claims abstract description 78
- 229910052750 molybdenum Inorganic materials 0.000 title claims abstract description 20
- 239000011733 molybdenum Substances 0.000 title claims abstract description 18
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 150000004663 bisphosphonates Chemical class 0.000 claims abstract description 47
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 41
- 201000011510 cancer Diseases 0.000 claims abstract description 33
- 239000003446 ligand Substances 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 51
- 229910052748 manganese Inorganic materials 0.000 claims description 48
- 229910052720 vanadium Inorganic materials 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 229910052802 copper Inorganic materials 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- 239000002243 precursor Substances 0.000 claims description 21
- 150000002500 ions Chemical class 0.000 claims description 20
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims description 19
- 229910052723 transition metal Inorganic materials 0.000 claims description 15
- 150000003624 transition metals Chemical class 0.000 claims description 15
- 229910004619 Na2MoO4 Inorganic materials 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 239000011684 sodium molybdate Substances 0.000 claims description 13
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 claims description 13
- 229910052725 zinc Inorganic materials 0.000 claims description 13
- MMIPFLVOWGHZQD-UHFFFAOYSA-N manganese(3+) Chemical compound [Mn+3] MMIPFLVOWGHZQD-UHFFFAOYSA-N 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 229910052707 ruthenium Inorganic materials 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 208000018084 Bone neoplasm Diseases 0.000 claims description 10
- -1 Ru or Pt Chemical class 0.000 claims description 10
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 8
- 229910052742 iron Inorganic materials 0.000 claims description 8
- 150000001455 metallic ions Chemical class 0.000 claims description 8
- 229910052697 platinum Inorganic materials 0.000 claims description 8
- 206010005949 Bone cancer Diseases 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 230000007704 transition Effects 0.000 claims description 7
- 229910001428 transition metal ion Inorganic materials 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 5
- 229940062527 alendronate Drugs 0.000 claims description 5
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 claims description 4
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical group CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 201000009036 biliary tract cancer Diseases 0.000 claims description 4
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 4
- 201000011061 large intestine cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 238000005580 one pot reaction Methods 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 230000007717 exclusion Effects 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 210000003445 biliary tract Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 210000002429 large intestine Anatomy 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000011572 manganese Substances 0.000 description 74
- 239000000243 solution Substances 0.000 description 24
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 19
- 230000003647 oxidation Effects 0.000 description 16
- 238000007254 oxidation reaction Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000005291 magnetic effect Effects 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000000449 magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 102000016914 ras Proteins Human genes 0.000 description 5
- 108010014186 ras Proteins Proteins 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 5
- 229960004276 zoledronic acid Drugs 0.000 description 5
- OJISWRZIEWCUBN-QIRCYJPOSA-N (E,E,E)-geranylgeraniol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CO OJISWRZIEWCUBN-QIRCYJPOSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100030708 GTPase KRas Human genes 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 238000005388 cross polarization Methods 0.000 description 4
- 238000005384 cross polarization magic-angle spinning Methods 0.000 description 4
- XWRJRXQNOHXIOX-UHFFFAOYSA-N geranylgeraniol Natural products CC(C)=CCCC(C)=CCOCC=C(C)CCC=C(C)C XWRJRXQNOHXIOX-UHFFFAOYSA-N 0.000 description 4
- OJISWRZIEWCUBN-UHFFFAOYSA-N geranylnerol Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCO OJISWRZIEWCUBN-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000013823 prenylation Effects 0.000 description 4
- 238000004051 1H MAS NMR Methods 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000013460 polyoxometalate Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000004738 31P MAS NMR Methods 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000005262 Chondroma Diseases 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 101710113436 GTPase KRas Proteins 0.000 description 2
- 108010026318 Geranyltranstransferase Proteins 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000012565 NMR experiment Methods 0.000 description 2
- 208000000035 Osteochondroma Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000005415 magnetization Effects 0.000 description 2
- 238000005404 magnetometry Methods 0.000 description 2
- JKQOBWVOAYFWKG-UHFFFAOYSA-N molybdenum trioxide Chemical compound O=[Mo](=O)=O JKQOBWVOAYFWKG-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910052701 rubidium Inorganic materials 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- VWZQCRAEGAWKBW-UHFFFAOYSA-N 1,3-dioxa-2$l^{6},4$l^{6}-dimolybdacyclobutane 2,2,4,4-tetraoxide Chemical compound O=[Mo]1(=O)O[Mo](=O)(=O)O1 VWZQCRAEGAWKBW-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 238000004679 31P NMR spectroscopy Methods 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 208000010126 Chondromatosis Diseases 0.000 description 1
- 208000019591 Chondromyxoid fibroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000034715 Enchondroma Diseases 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 102100035111 Farnesyl pyrophosphate synthase Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229910010171 Li2MoO4 Inorganic materials 0.000 description 1
- 238000005004 MAS NMR spectroscopy Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910017311 Mo—Mo Inorganic materials 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910017673 NH4PF6 Inorganic materials 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 201000011436 Ossifying Fibroma Diseases 0.000 description 1
- 229910018828 PO3H2 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229910019032 PtCl2 Inorganic materials 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 229910019891 RuCl3 Inorganic materials 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- DEWVXEPIOZAMIY-UHFFFAOYSA-J [Mo+4].[O-]P([O-])=O.[O-]P([O-])=O Chemical class [Mo+4].[O-]P([O-])=O.[O-]P([O-])=O DEWVXEPIOZAMIY-UHFFFAOYSA-J 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000000006 cell growth inhibition assay Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 208000020719 chondrogenic neoplasm Diseases 0.000 description 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005564 crystal structure determination Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- GBHRVZIGDIUCJB-UHFFFAOYSA-N hydrogenphosphite Chemical class OP([O-])[O-] GBHRVZIGDIUCJB-UHFFFAOYSA-N 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000005302 magnetic ordering Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000079 presaturation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002468 redox effect Effects 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 238000010996 solid-state NMR spectroscopy Methods 0.000 description 1
- 238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000000087 superconducting quantum interference device magnetometry Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
- C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
- C07F19/005—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00 without metal-C linkages
Definitions
- the present invention is generally dedicated to compounds for use for treating cancer.
- the present invention more particularly concerns polyoxomolybdate- bisphosphonate complexes containing a biologically active bisphosphonate ligand, further containing a heterometallic ion, different from molybdenum, for use in treating cancer.
- Polyoxometalates constitute a large family of anionic metal oxide clusters of d-block transition metals in high oxidation states (W VI , Mo v ' VI , V IV ' V ) and have a wide range of magnetic, redox, and catalytic properties.
- Biological applications, in particular anti-cancer properties have also been reported as for example in B. Hasenknopf, "polyoxometalates: introduction to a class of inorganic compounds and their biomedical applications ", Frontiers in Bioscience 10, 275-287, January 1, 2005.
- Bisphosphonates with the general formula H 2 O 3 PC(OH)(R)P0 3 H2, are one such class of bioactive molecules that are of interest in the development of hybrid species that might have both redox and a well as more conventional activity, as enzyme inhibitors.
- Bisphosphonates function by inhibiting the enzyme farnesyl diphosphate synthase (FPPS), which is involved in protein prenylation and cell signaling, and have been used for almost 40 years to treat bone resorption diseases.
- FPPS farnesyl diphosphate synthase
- some bisphosphonates also have activity against parasitic protozoa, as well as tumor cells.
- bisphosphonates have very recently been found in some systems to inactivate human epidermal growth factor receptors to exert anti-tumor activity, for example in T.
- BPs act as multidentate ligands and can form stable POM complexes.
- a broad range of POM/BP hybrids were previously reported for example in A. Banerjee et al. Chem. Soc. Rev. 2012, 41, 7590, in A. Dolbecq, et al, Chem. Commun. 2012, 48, 8299 and in L. Yang et al, Cryst. Growth. Des. 2013, 13, 2540, in connection to their anti-tumor cell growth inhibition activity.
- Mo(VI) complexes with BPs against tumor cell lines has been studied, suggesting synergistic effect between both organic and inorganic components (H.
- Oxomolybdate complexes with functionalized bisphosphonate ligands are described in Jean Daniel Compain et al. Chem Eur J. 2010, 16, 13741-13748, for example comprising alkaline counterion such as Li.
- alkaline counterion such as Li, Na, K or Rb are classical counter ions used in the coordination chemistry field for example in solutions, not encompassed within the meaning of a heterometal as defined herein after and do not show any impact on the anticancer activity.
- molybdenum bisphosphonates with molybdenum is known for its use in the field of catalysis.
- the present invention has for purpose to meet these needs.
- the present invention concerns a polyoxomolybdate-bisphosphonate complex containing a bisphosphonate ligand, wherein it further contains a heterometallic ion different from molybdenum, for use in treating cancer, said polyoxomolybdate- bisphosphonate complex having in particular the formula (I) as defined below.
- the present invention moreover relates to a method of preventing, inhibiting or treating cancer, which comprises at least one step consisting in administering to a patient suffering therefrom an effective amount of a polyoxomolybdate-bisphosphonate complex containing a bisphosphonate ligand, wherein it further contains a heterometallic ion different from molybdenum, and in particular of a complex as defined in formula (I) below.
- the present invention further relates to a process for the preparation of said complexes of formula (I) which are new, consisting in reacting
- a precursor selected from Na 2 MoO 4 and ( ⁇ 4 ) 6 ⁇ o 7 O 2 4 within a one-pot procedure in presence of a solvent, in particular water buffered between 3 and 8, BP, a M metal salt at a temperature ranging from 20 to 130°C, or
- a Na 2 MoO 4 precursor within a two step procedure comprising a first step using said Na 2 MoO 4 precursor in water at pH 3, followed by a second step using the obtained Mo 12 (BP) 4 in water at pH 3, a M precursor at a temperature ranging from 20 to 100°C.
- the present invention also provides pharmaceutical compositions comprising at least one of said complexes of formula (I) which are new.
- polyoxometalates or “POMs” as used herein refer to negatively charged aggregates of transition metals (mainly Vanadium, Molybdenum and Tungsten) with oxygen
- - "heterometal” means a 3d, 4d or 5d, in particular 3d and 4d and even more particularly a 3d transition metal
- heterometallic ion means a 3d or 4d, in particular a 3d transition metallic ion.
- Alkaline metals such as Li, Na, K, Rb are in particular not considered as heterometals. A list of heterometals as particularly adapted for the implementation of the present invention is given herein after.
- patient may extend to humans or mammals, such as cats or dogs.
- Figure 1 represents a complex of formula (la) as defined herein after.
- Figure 2 represents an intermediate compound of complex of formula (lb) as defined herein after.
- Figure 4 represents the ellipsoid scheme useful for the tumor volume calculation performed in example 1 1.3 hereinafter.
- a subject-matter of the present invention relates to a polyoxomolybdate-bisphosphonate complex containing a bisphosphonate ligand, wherein it further contains a heterometallic ion different from molybdenum, for use in treating cancer.
- the heterometallic ion is chosen among a 3d, 4d or 5d, in particular a 3d or 4d transition metal, and even more particularly a 3d transition metal.
- the present invention relates to a polyoxomolybdate-bisphosphonate complex containing a bisphosphonate ligand, wherein it further contains a heterometallic ion different from molybdenum, for use in treating cancer, having the following formula (I)
- x, y, z, t, r and n are independent integers
- y > x, and y ranges from 4 to 40
- r ranges from 0 to 8
- n an integer ranging from 2 to 16
- M represents a 3d transition metal ion selected from Mn, Fe, Cu, Zn, V and Co or a 4d or 5d transition metal like Ru and Pt,
- X represents an halogen atom or a water molecule
- BP represents a bisphosphonate, as defined herein after.
- the present invention relates to a compound wherein M is Fe, Pt, Mn, V or Ru, in particular Mn, V and Ru and more particularly Mn.
- the present invention relates to a compound of formula (I) wherein M is a 3d transition metal.
- M is Mn, Co, Cu, Zn or V, and even more preferably Mn, Cu, Co or V.
- M is Mn or Cu, Mn or Co, Mn or V, and even more particularly Mn in any oxidation state, and even particularly in oxidation state III.
- the present invention relates to a polyoxomolybdate-bisphosphonate complex as defined above, for use in treating cancer, wherein the polyoxometalate-bisphosphonate complex contains Mo 4 or Mo12 clusters and in particular a Mo 4 cluster.
- x 4 or 12. It may be noticed that once x is fixed, the other variable indices y, z and t naturally derive there from due to configurational constraints. With respect to the charge of the complex, n may vary between 2 and 16.
- an additional subject-matter of the present invention is a polyoxomolybdate-bisphosphonate complex having the following formula (la)
- BP is a bisphosphonate, in particular as defined hereinafter,
- n an integer ranging from 4 to 8
- M represents a 3d transition metal ion selected from Mn, Fe, Cu, Zn, V and Co or a 4d or 5d transition metal like Ru and Pt, and in particular M represents Mn, V or Ru, and more particularly Mn,
- Mo 4 O 12 Ale 2 V (V(IV)) and Mo 4 O 12 Eti 2 V (V(IV)) are disclosed in Y. Li, E.Wang et al propositionTwo new cantilever-type polyoxometalates constructed from ⁇ Mo 2 O 4 ⁇ 2+ fragments and diphosphonates" Dalton Trans 2010, 39, 1245; Mo 4 O 12 Ale 2 Mn (Mn(II)) in A. Dolbecq et al "Molybdenum bisphosphonates with
- the present invention relates to a compound of formula (la) wherein M is a 3d transition metal.
- M is Mn, Co, Cu, Zn or V, and even more preferably Mn, Cu, Co or V.
- M is Mn or Cu, Mn or Co, Mn or V, and even more particularly Mn in any oxidation state, and even particularly in oxidation state III.
- Said complex of formula (la) is represented in figure 1, wherein BP means bisphosphonate that may for example be alendronate or zoledronate, as explained herein after.
- the structures are centro-symmetric and contain two ⁇ 2 0 6 ⁇ dimeric units having face-shared Mo VI octahedra bound to an octahedrally coordinated metallic ion, M, which is located on a (pseudo) inversion center.
- Mo VI dimer molybdenum ions are connected to a pentadentate BP ligand via P-O- Mo and C-O-Mo bonds.
- the BP ligands are also bound to the central 3d transition metal ion or 4d transition metal.
- an additional subject-matter of the present invention is a compound of
- BP is a bisphosphonate in particular as defined hereinafter, n represents an integer ranging from 8 to 16,
- M represents a 3d transition metal ion selected from Mn, Fe, Cu, Zn, V and Co or a 4d or 5d transition metal like Ru and Pt, and in particular M represents Pt, and X represents a halogen atom or a water molecule.
- the structures may be described as the connection of four trimeric ⁇ Mo 3 O 8 ⁇ units via two oxygen atoms, one from a P-0 bond and one from a Mo-0 bond.
- the heterometallic ion M is connected to the complex via chelating groups present on the R arm of the BP ligand.
- the present invention relates to a compound of formula (lb) wherein M is a 3d transition metal.
- M is Mn, Co, Cu, Zn or V, and even more preferably Mn, Cu, Co or V.
- M is Mn or Cu, Mn or Co, Mn or V, and even more particularly Mn in any oxidation state, and even particularly in oxidation state III.
- the heterometallic ion different from molybdenum of the polyoxomolybdate- bisphosphonate complex according to the present invention, in particular of formula (I), (la) or (lb) may exist in various oxidation states which are all included in the framework of the present invention.
- the oxidation state of said heterometallic ion may be determined by magnetic measurements.
- Mn and Fe may exist in oxidation state II or III; V may exist in oxidation state IV or V; Ru preferably exists in oxidation state III.
- polyoxomolybdate-bisphosphonate complexes according to the present invention encompassing Mn as heterometallic ion may implement Mn in the oxidation state II or III, as in particular illustrated in examples 1 and 8 for the synthesis of compounds 6 and 9 of table 1 hereinafter.
- the structure of the complexes may be determined by using single crystal X- ray diffraction, elemental analysis, IR spectrometry, magnetic susceptibility and ID and 2D solid state NMR according to methods known to the man skilled in the art.
- the structure of the complexes may be determined by solid state NMR spectrometry, as it is for example illustrated herein after for complexes with Pt.
- the complexes may be in the form of variable supramolecular arrangements due to hydrogen bonding interactions depending on the nature of the organic arm of the BP ligands. All of said supramolecular arrangements also form part of the present invention.
- the complex of the present invention can be prepared by conventional methods of polyoxometalate synthesis practiced by those skilled in the art.
- the general reaction sequences outlined below represent general methods useful for preparing the complexes of the present invention and are not meant to be limiting in scope or utility.
- the synthetic routes may be different depending on the additional heterometallic element.
- the synthesis is based on the use of one precursor, for example selected from Na 2 MoO 4 , (NH 4 ) 6 Mo 7 0 24 , MoO 3 and Li 2 MoO 4 , and in particular from Na 2 MoO 4 and (NH 4 ) 6 Mo 7 0 24 within a one-pot procedure similar to that used for the Cr in -containing molybdobisphosphonates as described in A. Saad et al., J. Clust. Sci. 2014, 25, 795, in the presence of a solvent, the BP, the M metal salt, in a pH ranging from 3 to 8, and in particular from 6 to 7.5, and preferably under stirring.
- one precursor for example selected from Na 2 MoO 4 , (NH 4 ) 6 Mo 7 0 24 , MoO 3 and Li 2 MoO 4 , and in particular from Na 2 MoO 4 and (NH 4 ) 6 Mo 7 0 24 within a one-pot procedure similar to that used for the Cr in -containing molybdobisphosphonates as described
- Said reaction may be carried out at a temperature ranging from 20 to 130°C, for example during a period ranging from 5 minutes to 20 hours. Said step may be followed by a cooling at room temperature and a slow evaporation after centrifugation and/or filtration to recover a fine powder.
- the solvent may be water.
- the pH may be adjusted by the presence of a buffer, for example a CH 3 COONH 4 /CH 3 COOH buffer or a CH 3 COOLi/CH 3 COOH or CH 3 COONa/CH 3 COOH buffer, for example in a concentration ranging from 0.5 to 2M.
- the metal salt may be selected from Mn(CH 3 COO) 3 2H 2 0, FeCl 3 -6H 2 0, Cu(CH 3 COO) 2 H 2 0, NaV0 3 , VOSO 4 -5H 2 0, RuCl 3 xH 2 0, PtCl 2 (DMSO) 2 , Zn(CH 3 COO) 2 .2H 2 0 and Co(CH 3 COO) 2 4H 2 0.
- the complex of general formula (lb) can be prepared according to scheme 2 below.
- the synthesis is based on a two step procedure.
- the first step may be carried out in a solvent, such as water, in the presence of the precursor Na 2 MoO 4 , a BP, in a pH between 3 and 5, and preferably under stirring.
- Said first step may be carried out at a temperature ranging from 20 to 90°C for example during a period ranging from 10 minutes to 1 hour.
- Said step may be followed by a cooling at room temperature and a slow evaporation after centrifugation and/or filtration to recover a fine powder.
- the second step may be implemented by reacting the powder as obtained in the first step, i.e. Mo 12 (BP) 4 , in a solvent, such as water, in the presence of the M precursor, in a pH ranging from 3 to 5, and preferably under stirring.
- Said second step may be carried out at a temperature ranging from 20 to 90°C, for example during a period ranging from 10 minutes to 1 hour. Said step may be followed by a cooling at room temperature and a slow evaporation after centrifugation and/or filtration to recover a fine powder.
- the M precursor may be selected from Pt(DMSO)2Cl2.
- the present invention further relates to a synthetic preparation process for obtaining a polyoxomolybdate which are new, consisting in reacting
- a precursor selected from Na 2 MoO 4 and ( ⁇ 4 ) 6 Mo 7 O 24 within a one-pot procedure in presence of a solvent, in particular water buffered between 3 and 8, BP, a M metal salt at a temperature ranging from 20 to 130°C, or
- a Na 2 MoO 4 precursor within a two step procedure comprising a first step using said Na 2 MoO 4 precursor in presence of a solvent, in particular water buffered between 3 and 5, followed by a second step using the obtained Mo 12 (BP) 4 in presence of a solvent, in particular water buffered between 3 and 5, BP, a M precursor at a temperature ranging from 20 to 90°C.
- a solvent in particular water buffered between 3 and 5
- BP Mo 12
- M precursor at a temperature ranging from 20 to 90°C.
- a solution of Mo VI ions is simply prepared by dissolving the precursor in water.
- the pH value has to be controlled.
- the BP/Mo and M/Mo ratios are crucial parameters.
- the order of addition of reactants plays also a role. Temperature can be increased up to 130°C in case of poorly soluble BP. Addition of extra counter-cations (Na + , Rb ) can favor the crystallization.
- Bisphosphonates that may be implemented in the framework of the present invention may be selected from all the classical ones as already disclosed in the literature. Among known bisphosphonates, the following may be cited: etidronate, pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate and zoledronate.
- Bisphosphonates in the framework of the present invention may be defined as compounds of general formula H 2 O 3 PC(OH)(R)PO 3 H 2 (A)
- n 1, 2 or 3
- R3 and R4 independently of each other are selected from a hydrogen atom, a halogen, a (C 1 -C 4 )alkyl group and a (C 1 -C 4 )alkoxy group, and
- Q represents a phenyl group or a heteroaryl group, said phenyl and heteroaryl being optionally substituted with one to three substituents chosen from a (C 1 -C 1 5)alkyl group, a halogen atom, a hydroxyl group, an OR1 group, a SRI group, a NR1R2 group or a CN group, and
- Rl and R2 independently represent a hydrogen atom, a (C 1 -C 6 )alkyl or a -(CH 2 ) X X, wherein x is 1, 2 or 3, and X has the same meaning as Q.
- alkyl refers to a linear or branched, saturated aliphatic hydrocarbon group.
- a (C 1 -C 6 )alkyl group denotes a linear or branched carbon chain of 1 to 6 carbon atoms. Examples are, but are not limited to methyl, ethyl, propyl, isopropyl, butyl and methylbutyl.
- heteroaryl denotes a 5- or 6-membered aromatic ring comprising 1 or 2 heteroatoms
- heteroatom is understood to mean nitrogen, oxygen or sulphur.
- the heteroaryl comprises at least one nitrogen atom.
- the heteroaryl comprises only nitrogen as heteroatom(s).
- the heteroaryl comprises from 1 to 4 nitrogen atoms, and preferably 1 or 2 nitrogen atoms. Mention may be made of pyridine, thiazole, pyrrole, pyrazole, imidazole and triazole, and more particularly of imidazole.
- heteroaryl includes all the positional isomers.
- a first subgroup of compounds is formed from compounds for which R represents a (C 1 -C 8 )alkyl group, optionally substituted by a NR1R2 group, with Rl and R2 having the same meaning as described above.
- n 1 , 2 or 3
- R3 and R4 independently of each other are selected from a hydrogen atom, a halogen, a (C 1 -C 4 )alkyl group and a (C 1 -C 4 )alkoxy group, and
- Q represents a phenyl group or a heteroaryl group, said phenyl and heteroaryl being optionally substituted with one to three substituents chosen from a (C 1 -C 15 alky 1 group, a halogen atom, a hydroxyl group, an OR1 group, a SRI group, a NR1R2 group or a CN group.
- the bisphosphonate is defined as a
- R4 are hydrogen atoms and Q is group, optionally substituted by a
- the bisphosphonate is (C 1 -C 15 )alkyl group, in particular a (C 1 -C 8 ) alkyl group.
- the bisphosphonate is
- n 1
- R3 and R4 are hydrogen atoms and Q is a group, where R5 represents a hydrogen atom or a (C 1 -C 15 )alkyl group, in particular a (C 1 -C 8 ) alkyl group.
- R5 represents a hydrogen atom or a (C 1 -C 15 )alkyl group, in particular a (C 1 -C 8 ) alkyl group.
- This particular subgroups encompasses compound BPH-1222 as disclosed in Yifeng Xia et al, "a combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin", ScienceTranslationMedicine, Vol6, issue 263, 2014, 263ral61 , and illustrated in example 9 hereinafter (compound 9 of table 1 hereinafter).
- the present invention is directed to a compound of formula (I) for use in treating cancer, wherein BP is a compound of formula (A) wherein R represents a (C 1 -C 8 )alkyl group, optionally substituted by a NR1R2
- Rl and R2 independently represent a hydrogen
- R5 represents a hydrogen atom or a (C 1 -C 8 )alkyl group.
- the present invention relates to a polyoxomolybdate-bisphosphonate complex of formula (I) as defined above, for use in treating cancer, wherein x, y, z, t, n and M are as defined above and wherein the bisphosphonate ligand is chosen among alendronate, zolendronate, BPC 8 NH2, AlePy, BPH-1222 and BPC9, and more particularly wherein M is Mn, Co, Cu, Zn or V, and even more preferably Mn, Cu, Co or V. According to a particular embodiment, M is Mn or Cu, Mn or Co, Mn or V, and even more particularly is Mn.
- the complexes as defined in the present invention are useful in the prevention and treatment of cancer.
- the term “preventing” or “prevention” means to reduce the risk of onset or slow the occurrence of a given phenomenon, namely, a cancer. Accordingly, the term “preventing” or “prevention” may encompass the "reduction of the likelihood of occurrence ' " or the “reduction of the likelihood of progression” of a given phenomenon.
- the following type of cancer may more particularly be treated by the complex according to the present invention: bone cancer, colorectal cancer, pancreatic cancer, lung cancer including non-small cell lung cancer, breast cancer, large intestine cancer, biliary tract cancer, bladder cancer, gall bladder cancer, thyroid cancer, melanoma, liver cancer, uterine/cervical cancer, oesophageal cancer, kidney cancer, ovarian cancer, prostate cancer, head and neck cancer, and stomach cancer, etc.
- lung cancer including non-small cell lung cancer, breast cancer, large intestine cancer, biliary tract cancer, bladder cancer, gall bladder cancer, thyroid cancer, melanoma, liver cancer, uterine/cervical cancer, oesophageal cancer, kidney cancer, ovarian cancer, prostate cancer, head and neck cancer, and stomach cancer, etc.
- Metastatic lesions such as the ones associated with the previous types of cancers are also considered.
- the present invention is more particularly directed to the prevention and/or treatment of bone, lung, large intestine, biliary tract, breast and pancreatic cancer.
- the present invention is directed to the prevention and/or treatment of bone cancer (also referred herein as "bone tumor” or “malignant bone tumor”); which includes bone cancer selected from a group consisting of: primary bone tumors and secondary bone tumors.
- bone cancer also referred herein as "bone tumor” or “malignant bone tumor”
- primary bone tumors and secondary bone tumors.
- Bone cancer may include any tumor of bones and cartilages, in particular any osseous and chondromatous neoplasmas, such as the ones selected from a group consisting of: bone sarcoma, osteoma, osteosarcoma, chondroma, osteochondroma, chondrosarcoma, ecchondroma, enchondroma, osteochondroma, chondromyxoid fibroma, ossifying fibroma, fibrosarcoma, chondroblastoma, multiple myeloma, adamatinoma and Ewing's sarcoma.
- any osseous and chondromatous neoplasmas such as the ones selected from a group consisting of: bone sarcoma, osteoma, osteosarcoma, chondroma, osteochondroma, chondrosarcoma, ecchondroma, enchondroma, osteo
- the complex according to the invention is particularly suitable for treating a cancer associated with Human Ewing Sarcoma (anaplastic osteosarcoma).
- the present invention is more particularly directed to a method for treating patients suffering from a Ras-associated cancer, wherein said cancer is preferably associated with overactivated Ras.
- the cancer cells will harbor the ras oncogene.
- the present invention is directed to a method for treating patients suffering from a Ras-associated cancer, wherein said Ras protein is selected from HRAS, KRAS and NRAS.
- said Ras protein is selected from HRAS, KRAS and NRAS.
- the one skilled in the art may notably refer to the article of Miller et al. (2012, Frontiers in Genetics, Vol. 2, Article 100: 1-9).
- the present invention relates to methods for treating patients suffering from a cancer wherein Ki-Ras comprises one or more mutations, which encompasses cancers wherein the Ki-Ras one or more mutations are present and are are selected in a group comprising CYS 12 , ASP 12 , VAL 12 , ALA 12 , SER 12 , ARG 12 , PHE 12 , ASP 13 , CYS 13 , ARG 13 , SER 13 , VAL 13 , ALA 13 , HIS 61 , ARG 61 and ASP 61 . (See Miller et al, 2012, Supra).
- an effective amount of a said compound may be administered to a patient suffering from cancer.
- a complex according to the invention is chosen among:
- the present invention extends to complexes (1) to (4) and (6) to (13). It more particularly relates to compounds (1), (2), (3), (4), (6), (7), (9) and (11), and even more particularly to compounds (6), (9) and (11).
- compositions according to the invention are given as illustrations with no limiting nature.
- the spin rate was 20 kHz for ID 1H MAS, ID 31 P ⁇ 1H ⁇ MAS, and 2D 31 P ⁇ 1H ⁇ CPMAS HETCOR, and 10 kHz for 2D 3 1 P ⁇ 1 H ⁇ - 31 P ⁇ 1 H ⁇ DQ-SQ MAS.
- 1H chemical shifts were referenced with respect to external TMS, while 31 P chemical shifts were referenced with respect to 85% H 3 PO 4 , with an accuracy of ⁇ 0.4 ppm.
- H 5 Ale 0.97 g, 2.80 mmol
- FeCl 3 -6H 2 0 0.78 g, 1.4 mmol
- the solution was then stirred for 40 min at 90 °C until clear. After cooling to room temperature, a fine powder was filtered off and the solution left to evaporate. Yellow crystals appeared after 30 min and were collected after two days.
- IR (FTR): v (cm -1 ) 1623(m), 1529(w), 145 l(m), 1145(sh), 1126(s), 1056(sh), 1026(s), 965(w), 917(m), 874(s), 794(m), 760(m), 682(sh), 647(m), 541(m), 520(m), 489(m), 401(m).
- the MAS NMR spectrum of the platinum complex Mo 12 (AlePy) 4 Pt 4 shows two signals, centered at ca.
- the 1H MAS spectrum of Mo 12 (AlePy) 4 consists of a dominant resonance at 4.2 ppm due to water molecules, with a very small shoulder at ca. 2 ppm, and two other signals, centred at ⁇ 8 and 18.4 ppm.
- the resonances around 2 and 8 ppm are assigned to methylene and aromatic protons of the AlePy ligands.
- the signal at ca. 18 ppm arises from acidic protons and the results of a 2D 31 P ⁇ 1 H ⁇ HETCOR experiment clearly indicates close proximity between this/these proton/s and the phosphorus responsible for the resonance at 20 ppm.
- SQUID measurements confirm the +2 oxidation state of the Mn ions.
- the H 2 P(V salt of BPH-1222, [BPH-1222]H 2 PO 4 was synthesized following the synthesis reported in Y. Xia et al. Sci. Transl. Med. 2014, 6, 263ral61.
- the H 2 PO 4 - salt was transformed in the lithium salt Li 2 [BPH-1222] by addition of LiOH.
- [BPH- 1222]H 2 PO 4 (0.500 g, 1 mmol) was dissolved in 10 mL of water. 1M LiOH was then added until pH 7. The solution was stirred for 24h. The solid was collected by filtration and washed with MeOH.
- EDX measurements confirm the Mo/P and Mo/Mn ratios.
- ⁇ D ⁇ value is higher than those usually determined with six-coordinated Mn 11 complexes (for example C. Duboc et al. Chem. Eur. J. 2008, 14, 6498).
- polyoxometalate ligands can induce a strong magnetic anisotropy, as exemplified by the D value of +1.46 cm -1 found in the Mn 11 complex
- Example 11.1 Cell-growth inhibition assays
- Human tumor cell lines MCF-7 (breast adenocarcinoma were obtained from the National Cancer Institute and maintained at 100% humidity and 5% C0 2 at 37 °C. Cell lines were cultured in RPMI-1640 medium supplemented with 2 mM L-glutamine and 10%) fetal bovine serum (Gibco, Grand Island, NY) at 37°C in a 5% C0 2 atmosphere with 100%) humidity. Compound stock solutions were typically prepared in water at a concentration of 0.04 M. A broth microdilution method was used to determine the bisphosphonate growth inhibition IC 50 values.
- Compounds were half log serial diluted using cell culture media into 96-well TC-treated round bottom plates (Corning Inc., Corning, NY) typically from 1264 ⁇ to 40 nM, but in some cases compounds were run over a larger concentration range to enable accurate IC50 determinations.
- Cells were plated at a density of 5000 cells/well. Cells were then incubated under the same culture conditions for 4 days at which time an MTT ((3-(4,5-dimethylthi-azole-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation assay (ATCC, Manassas, VA) was performed to obtain dose response curves.
- MTT ((3-(4,5-dimethylthi-azole-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation assay
- Results are gathered in table 3 hereinafter. The results are shown on a molar basis (IC 50 values, in ⁇ ) as well as on a per-bisphosphonate basis, which is more logical when comparisons are to be made with the pure bisphosphonates.
- Both the heteroatom as well as the bisphosphonate are having effects on cell growth inhibition, although addition of Mn(II)Cl 2 alone has essentially no effect (IC 50 -740 ⁇ ) on cell growth.
- Example 1 1.2 Evidence for significant targeting of protein prenylation pathways
- Protocol Cell growth "rescue" experiments with geranylgeraniol were carried out as described previously, and namely in Y. Zhang, et al J. Am. Chem. Soc. 2009, 131 , 51.
- An increase in the IC 50 indicates a direct role for the bisphosphonate moiety in cell growth inhibition.
- Tumor volumes were calculated using the following formula: volume (mm 3 ) ) (smallest diameter)2 x (largest diameter)/2. All animal experiments were conducted according to the guidelines of the Institutional Animal Care and Use Committee, and the protocol was approved by the Ethics Committee for Experimental Animals of Hiroshima University. Statistical significance was determined by one-way ANOVA and Fisher's PLSD method, using Statcel (OMS Ltd., Saitama, Japan); p ⁇ 0.05 was considered to be significant.
- the calculation for the tumor volume is as follows, in accordance with the scheme represented in figure 4
- Results The results are gathered in table 6 as follows
- the present invention is also related to the use of at least a compound chosen among a compound of any one of formula (I), (la) or (lb) as defined above, and compounds (1) to (13) as defined above, for the manufacture of a pharmaceutical composition intended for the treatment of cancer.
- the present invention also encompasses pharmaceutical compositions comprising at least a compound selected from the complexes of formulae (la) with the exclusion of complexes Mo 4 O 12 Eti 2 Mn (Mn(II)), Mo 4 O 12 Ale 2 Mn (Mn(II)), Mo 4 O 12 Ale 2 V (V(IV)), Mo 4 O 12 Eti 2 Fe (Fe(III)) and Mo 4 O 12 Eti 2 V (V(IV)) and (lb) as defined above and compounds (1) to (4) and (6) to (13) as defined above or any pharmaceutically acceptable salt thereof.
- the present invention in particular encompasses pharmaceutical compositions comprising at least a compound selected from compounds (1), (2), (3), (4), (6), (7), (9) and (1 1), in particular selected from compounds (6), (9) and (1 1).
- compositions contain an effective amount of said compound, and one or more pharmaceutical excipients.
- excipients are selected according to the dosage form and the desired mode of administration.
- the complexes as defined in the present invention may be suitable for any route of administration. Accordingly, and in a non-exhaustive manner, the complexes are suitable for oral administration, enteral administration, parenteral administration, topical administration, and/or inhalation.
- a route of administration may be selected from the group consisting of: epidural, intracerebral, intracerebroventricular, subcutaneous, transdermal, intradermal, sublingual, buccal, extra-amniotic, nasal, intra-arterial, intra-venous, intraarticular, intra-cardiac, intra-carvenous, intra-lesional, intra-muscular, intra-ocular, intra- osseous, intra-peritoneal, intra-pulmonary, intra-thecal, intra-uterine, intra-vaginal, intravesical, intra-vitreal, sublingual administration, and trans-mucosal administration.
- the complexes as defined in the present invention are suitable for parenteral and/or intraperitoneral administration.
- any pharmaceutical form which is suitable for enteral, parenteral and/or intraperitoneral administration, in association with appropriate excipients, for example in the form of plain or coated tablets, hard gelatine, soft shell capsules and other capsules, suppositories, or drinkable, such as suspensions, syrups, or injectable solutions or suspensions, in doses which enable the daily administration of from 0.1 to 1000 mg of active substance.
- the present invention further relates to a method of treatment of patients suffering from cancer, which comprises at least a step of administration to a patient suffering thereof of an effective amount of a compound of any one of formulae (I), (la) or (lb) as defined above and (1) to (13).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a polyoxomolybdate-bisphosphonate complex containing a bisphosphonate ligand, wherein it further contains a heterometallic ion different from molybdenum, for use in treating cancer. It further relates to novel polyoxomolybdate-bisphosphonate complexes containing a bisphosphonate ligand, wherein it further contains a heterometallic ion different from molybdenum, to their preparation process and pharmaceutical composition containing them.
Description
POL YOXOMOL YBD ATE-BI SPHO SPHO ATE COMPLEX CONTAINING A HETEROMETALLIC ION DIFFERENT FROM MOLYBDENUM
The present invention is generally dedicated to compounds for use for treating cancer.
The present invention more particularly concerns polyoxomolybdate- bisphosphonate complexes containing a biologically active bisphosphonate ligand, further containing a heterometallic ion, different from molybdenum, for use in treating cancer.
Polyoxometalates (POMs) constitute a large family of anionic metal oxide clusters of d-block transition metals in high oxidation states (WVI, Mov'VI, VIV'V) and have a wide range of magnetic, redox, and catalytic properties. Biological applications, in particular anti-cancer properties, have also been reported as for example in B. Hasenknopf, "polyoxometalates: introduction to a class of inorganic compounds and their biomedical applications ", Frontiers in Bioscience 10, 275-287, January 1, 2005.
Bisphosphonates (BPs), with the general formula H2O3PC(OH)(R)P03H2, are one such class of bioactive molecules that are of interest in the development of hybrid species that might have both redox and a well as more conventional activity, as enzyme inhibitors. Bisphosphonates function by inhibiting the enzyme farnesyl diphosphate synthase (FPPS), which is involved in protein prenylation and cell signaling, and have been used for almost 40 years to treat bone resorption diseases. In addition, some bisphosphonates also have activity against parasitic protozoa, as well as tumor cells. In addition, bisphosphonates have very recently been found in some systems to inactivate human epidermal growth factor receptors to exert anti-tumor activity, for example in T. Yuen, et al, Proc. Natl. Acad. Sci. USA 2014, 11, 17989 and in A. Stachnik et al, Proc. Natl. Acad. Sci. USA 2014. I l l, 17995. They are known to activate human gamma-delta T cells to kill tumor cells; they switch macrophages from a tumor promoting to tumor killing phenotype and they inhibit angiogenesis. It has also been demonstrated that bisphosphonates are able to block ras signaling pathways.
Once deprotonated, BPs act as multidentate ligands and can form stable POM complexes. A broad range of POM/BP hybrids were previously reported for example in A. Banerjee et al. Chem. Soc. Rev. 2012, 41, 7590, in A. Dolbecq, et al, Chem. Commun. 2012, 48, 8299 and in L. Yang et al, Cryst. Growth. Des. 2013, 13, 2540, in connection to
their anti-tumor cell growth inhibition activity. In particular, the activity of Mo(VI) complexes with BPs against tumor cell lines has been studied, suggesting synergistic effect between both organic and inorganic components (H. El Moll et al., "polyoxometalales functionalized by bisphonate ligands: synthesis, structural, magnetic and spectroscopic characterizations and activity on tumor cell lines", Inorg. Chem. 2012, 51, 7921-7931).
Oxomolybdate complexes with functionalized bisphosphonate ligands are described in Jean Daniel Compain et al. Chem Eur J. 2010, 16, 13741-13748, for example comprising alkaline counterion such as Li. However, alkaline counterion such as Li, Na, K or Rb are classical counter ions used in the coordination chemistry field for example in solutions, not encompassed within the meaning of a heterometal as defined herein after and do not show any impact on the anticancer activity.
From Hani El Moll et al., Inorg. Chem. 2012, 51, 7921-7931 are known polyoxometalates functionalized by bisphosphonate ligands demonstrating an activity on tumor cell lines.
Moreover, as disclosed in Jingyang Niu et al, Chem Eur. J. 2012, 18, 6759-
6762 and Ali Saad et al, J. Clust Sci 2014, 25:795-809, molybdenum bisphosphonates with molybdenum is known for its use in the field of catalysis.
There is a continuing need for proposing polyoxomolybdate-bisphosphonate complexes demonstrating anti-cancer activity, and in particular improved anti-cancer activity.
There is also a need to provide the skilled person with polyoxomolybdate- bisphosphonate complexes showing synergistic activity in comparison to polyoxomolybdate complex alone and the corresponding BP alone. In other words, there is a need to propose polyoxomolybdate-bisphosphonate complexes with an activity of combined origin, i.e. metal based and also demonstrating significant effect on protein prenylation.
There is an additional need to provide the skilled person with new chemical entities increasing activity in tumor cell killing.
The present invention has for purpose to meet these needs.
Unexpectedly, the inventors have found that the addition of a heterometallic element different from molybdenum imparts interesting properties, including perhaps, targeting of isoprenoid biosynthesis by the bisphosphonate ligands.
Therefore, the present invention concerns a polyoxomolybdate-bisphosphonate complex containing a bisphosphonate ligand, wherein it further contains a heterometallic ion different from molybdenum, for use in treating cancer, said polyoxomolybdate- bisphosphonate complex having in particular the formula (I) as defined below.
The present invention moreover relates to a method of preventing, inhibiting or treating cancer, which comprises at least one step consisting in administering to a patient suffering therefrom an effective amount of a polyoxomolybdate-bisphosphonate complex containing a bisphosphonate ligand, wherein it further contains a heterometallic ion different from molybdenum, and in particular of a complex as defined in formula (I) below.
Some of said complexes of formula (I) are new and also form part of the present invention, and subfamilies (la) and (lb) as defined below, which pertain to the complex of formula (I) are also encompassed within the scope of the present invention.
The present invention further relates to a process for the preparation of said complexes of formula (I) which are new, consisting in reacting
(i) a precursor selected from Na2MoO4 and (ΝΗ4)6Μo7O24 within a one-pot procedure in presence of a solvent, in particular water buffered between 3 and 8, BP, a M metal salt at a temperature ranging from 20 to 130°C, or
(ii) a Na2MoO4 precursor within a two step procedure comprising a first step using said Na2MoO4 precursor in water at pH 3, followed by a second step using the obtained Mo12(BP)4 in water at pH 3, a M precursor at a temperature ranging from 20 to 100°C.
The present invention also provides pharmaceutical compositions comprising at least one of said complexes of formula (I) which are new.
Due to multiple site of action of the complexes according to the present invention, it is expected to decrease the likelihood of drug resistance, which is a great advantage for anti-cancer drugs.
In the context of the present invention, the expression:
- "polyoxometalates" or "POMs" as used herein refer to negatively charged aggregates of transition metals (mainly Vanadium, Molybdenum and Tungsten) with oxygen,
- "heterometal" means a 3d, 4d or 5d, in particular 3d and 4d and even more particularly a 3d transition metal and "heterometallic ion" means a 3d or 4d, in particular a 3d transition metallic ion. Alkaline metals such as Li, Na, K, Rb are in particular not considered as heterometals. A list of heterometals as particularly adapted for the implementation of the present invention is given herein after.
- "patient" may extend to humans or mammals, such as cats or dogs.
The terms "between... and..." and "ranging from... to..." should be understood as being inclusive of the limits, unless otherwise specified.
FIGURES
Figure 1 represents a complex of formula (la) as defined herein after. Figure 2 represents an intermediate compound of complex of formula (lb) as defined herein after.
Figure 3a represents XMT = f(7) curves related to the complexes Mo4Α1β2Μη and Mo4ZoI2M11. Figures b and c represent the M = f(H) curves related to the complexes Mo4Α1β2Μη and Mo4ZoI2M11 respectively recorded at 3, 4, 6 and 8 K.
Figure 4 represents the ellipsoid scheme useful for the tumor volume calculation performed in example 1 1.3 hereinafter.
POLYMOLYBDATE-BI SPHOSPHONATE COMPLEX
According to one aspect, a subject-matter of the present invention relates to a polyoxomolybdate-bisphosphonate complex containing a bisphosphonate ligand, wherein it further contains a heterometallic ion different from molybdenum, for use in treating cancer.
As defined above, the heterometallic ion is chosen among a 3d, 4d or 5d, in particular a 3d or 4d transition metal, and even more particularly a 3d transition metal.
According to a further aspect, the present invention relates to a polyoxomolybdate-bisphosphonate complex containing a bisphosphonate ligand, wherein it further contains a heterometallic ion different from molybdenum, for use in treating cancer, having the following formula (I)
[MoxOy(BP)zMtXr]n (I)
wherein
x, y, z, t, r and n are independent integers,
2 < x < 12,
y > x, and y ranges from 4 to 40,
z < x, and z ranges from 2 to 8,
t < x and t ranges from 1 to 10,
r ranges from 0 to 8,
n represents an integer ranging from 2 to 16,
M represents a 3d transition metal ion selected from Mn, Fe, Cu, Zn, V and Co or a 4d or 5d transition metal like Ru and Pt,
X represents an halogen atom or a water molecule, and
BP represents a bisphosphonate, as defined herein after.
All the diversity of nuclearities and shapes of the complexes form part of the present invention. As it will be apparent in the following, depending on the process and for example the precursors, the operating conditions (particularly pH and temperature), the assembly between the precursor and the ligand(s) comes out in various forms. This has been exemplified in a recent study (Inorg. Chem. 2012, 51 , 7921-7931) where it is shown that according to the pH value, three different nuclearities have been observed for the same BP: x = 1 at pH 7.5, x = 6 at pH 4.8 and x = 12 at pH 3.
According to a preferred embodiment, the present invention relates to a compound wherein M is Fe, Pt, Mn, V or Ru, in particular Mn, V and Ru and more particularly Mn.
According to another preferred embodiment, the present invention relates to a compound of formula (I) wherein M is a 3d transition metal. In a particularly preferred embodiment, M is Mn, Co, Cu, Zn or V, and even more preferably Mn, Cu, Co or V. According to a particular embodiment, M is Mn or Cu, Mn or Co, Mn or V, and even more particularly Mn in any oxidation state, and even particularly in oxidation state III.
According to a particular embodiment, the present invention relates to a polyoxomolybdate-bisphosphonate complex as defined above, for use in treating cancer, wherein the polyoxometalate-bisphosphonate complex contains Mo4 or Mo12 clusters and in particular a Mo4 cluster.
According to a further particular embodiment, x=4 or 12. It may be noticed that once x is fixed, the other variable indices y, z and t naturally derive there from due to configurational constraints. With respect to the charge of the complex, n may vary between 2 and 16.
According to another particular embodiment, an additional subject-matter of the present invention is a polyoxomolybdate-bisphosphonate complex having the following formula (la)
[Mo4O12(BP)2M]n- (Ia)
wherein
BP is a bisphosphonate, in particular as defined hereinafter,
n represents an integer ranging from 4 to 8, and
M represents a 3d transition metal ion selected from Mn, Fe, Cu, Zn, V and Co or a 4d or 5d transition metal like Ru and Pt, and in particular M represents Mn, V or Ru, and more particularly Mn,
with the exclusion of compounds Mo4O12Eti2Mn (Mn(II)), Mo4O12Ale2Mn
(Mn(II)), Mo4O12Ale2V (V(IV)), Mo4O12Et12Fe (Fe(III)) and Mo4O12Eti2V (V(IV)).
Mo4O12Ale2V (V(IV)) and Mo4O12Eti2V (V(IV)) are disclosed in Y. Li, E.Wang et al „Two new cantilever-type polyoxometalates constructed from {Mo2O4}2+ fragments and diphosphonates" Dalton Trans 2010, 39, 1245; Mo4O12Ale2Mn (Mn(II)) in A. Dolbecq et al "Molybdenum bisphosphonates with
Cr(III) or Mn(III) ions" J. Clust. Sci. 2014, 25, 795, and Mo4O12Eti2Fe (Fe(III)) and Mo4O12Eti2Mn (Mn(II)) are disclosed in Y. Zhou et al "A general synthesis approach in action: preparation and characterization of polyoxomolybdenum(VI) organophosphonates through oxidative Mo-Mo bond cleavage in {Mov 2O4} " CrystEng Comm 2012, 14, 4826.
According to another preferred embodiment, the present invention relates to a compound of formula (la) wherein M is a 3d transition metal. In a particularly preferred embodiment, M is Mn, Co, Cu, Zn or V, and even more preferably Mn, Cu, Co or V. According to a particular embodiment, M is Mn or Cu, Mn or Co, Mn or V, and even more particularly Mn in any oxidation state, and even particularly in oxidation state III.
Said complex of formula (la) is represented in figure 1, wherein BP means bisphosphonate that may for example be alendronate or zoledronate, as explained herein after.
According to this particular embodiment, the structures are centro-symmetric and contain two {Μο206} dimeric units having face-shared MoVI octahedra bound to an octahedrally coordinated metallic ion, M, which is located on a (pseudo) inversion center. In each MoVI dimer, molybdenum ions are connected to a pentadentate BP ligand via P-O- Mo and C-O-Mo bonds. The BP ligands are also bound to the central 3d transition metal ion or 4d transition metal.
According to another particular embodiment, an additional subject-matter of the present invention is a compound of
the following formula (lb)
[Mo12032(BP)4M4X8]n- (Ib)
wherein BP is a bisphosphonate in particular as defined hereinafter, n represents an integer ranging from 8 to 16,
M represents a 3d transition metal ion selected from Mn, Fe, Cu, Zn, V and Co or a 4d or 5d transition metal like Ru and Pt, and in particular M represents Pt, and X represents a halogen atom or a water molecule.
Said Mo12 core or intermediate compound of the complex of formula (lb) is represented in figure 2.
According to this particular embodiment, the structures may be described as the connection of four trimeric {Mo3O8} units via two oxygen atoms, one from a P-0 bond and one from a Mo-0 bond. The heterometallic ion M is connected to the complex via chelating groups present on the R arm of the BP ligand.
It may be noticed that in some abbreviated names of complexes according to the present invention, the elements O and X of the formulae are not always represented, as it will be apparent in table 1 and in the experimental part herein after.
According to another preferred embodiment, the present invention relates to a compound of formula (lb) wherein M is a 3d transition metal. In a particularly preferred embodiment, M is Mn, Co, Cu, Zn or V, and even more preferably Mn, Cu, Co or V. According to a particular embodiment, M is Mn or Cu, Mn or Co, Mn or V, and even more particularly Mn in any oxidation state, and even particularly in oxidation state III.
The heterometallic ion different from molybdenum of the polyoxomolybdate- bisphosphonate complex according to the present invention, in particular of formula (I), (la) or (lb) may exist in various oxidation states which are all included in the framework of the present invention.
The oxidation state of said heterometallic ion may be determined by magnetic measurements.
For example Mn and Fe may exist in oxidation state II or III; V may exist in oxidation state IV or V; Ru preferably exists in oxidation state III.
In particular the polyoxomolybdate-bisphosphonate complexes according to the present invention encompassing Mn as heterometallic ion may implement Mn in the oxidation state II or III, as in particular illustrated in examples 1 and 8 for the synthesis of compounds 6 and 9 of table 1 hereinafter.
The structure of the complexes may be determined by using single crystal X- ray diffraction, elemental analysis, IR spectrometry, magnetic susceptibility and ID and 2D solid state NMR according to methods known to the man skilled in the art.
In some cases, the structure of the complexes may be determined by solid state NMR spectrometry, as it is for example illustrated herein after for complexes with Pt.
The complexes may be in the form of variable supramolecular arrangements due to hydrogen bonding interactions depending on the nature of the organic arm of the BP ligands. All of said supramolecular arrangements also form part of the present invention.
The complex of the present invention can be prepared by conventional methods of polyoxometalate synthesis practiced by those skilled in the art. The general reaction sequences outlined below represent general methods useful for preparing the complexes of the present invention and are not meant to be limiting in scope or utility.
The synthetic routes may be different depending on the additional heterometallic element.
The complex of general formula (la) can be prepared according to scheme 1 below.
Scheme 1
The synthesis is based on the use of one precursor, for example selected from Na2MoO4, (NH4)6Mo7024, MoO3 and Li2MoO4, and in particular from Na2MoO4 and (NH4)6Mo7024 within a one-pot procedure similar to that used for the Crin-containing molybdobisphosphonates as described in A. Saad et al., J. Clust. Sci. 2014, 25, 795, in the presence of a solvent, the BP, the M metal salt, in a pH ranging from 3 to 8, and in particular from 6 to 7.5, and preferably under stirring. Said reaction may be carried out at a temperature ranging from 20 to 130°C, for example during a period ranging from 5 minutes to 20 hours. Said step may be followed by a cooling at room temperature and a slow evaporation after centrifugation and/or filtration to recover a fine powder.
According to this procedure, the solvent may be water. The pH may be adjusted by the presence of a buffer, for example a CH3COONH4/CH3COOH buffer or a CH3COOLi/CH3COOH or CH3COONa/CH3COOH buffer, for example in a concentration ranging from 0.5 to 2M. The metal salt may be selected from Mn(CH3COO)3 2H20, FeCl3-6H20, Cu(CH3COO)2 H20, NaV03, VOSO4-5H20, RuCl3 xH20, PtCl2(DMSO)2, Zn(CH3COO)2.2H20 and Co(CH3COO)24H20.
The complex of general formula (lb) can be prepared according to scheme 2 below.
(lb)
The synthesis is based on a two step procedure.
The first step may be carried out in a solvent, such as water, in the presence of the precursor Na2MoO4, a BP, in a pH between 3 and 5, and preferably under stirring. Said first step may be carried out at a temperature ranging from 20 to 90°C for example during a period ranging from 10 minutes to 1 hour. Said step may be followed by a cooling at room temperature and a slow evaporation after centrifugation and/or filtration to recover a fine powder.
The second step may be implemented by reacting the powder as obtained in the first step, i.e. Mo12(BP)4, in a solvent, such as water, in the presence of the M precursor, in a pH ranging from 3 to 5, and preferably under stirring. Said second step may be carried out at a temperature ranging from 20 to 90°C, for example during a period ranging from 10 minutes to 1 hour. Said step may be followed by a cooling at room temperature and a slow evaporation after centrifugation and/or filtration to recover a fine powder.
The M precursor may be selected from Pt(DMSO)2Cl2.
The present invention further relates to a synthetic preparation process for obtaining a polyoxomolybdate which are new, consisting in reacting
(i) a precursor selected from Na2MoO4 and (ΝΗ4)6Mo7O24 within a one-pot procedure in presence of a solvent, in particular water buffered between 3 and 8, BP, a M metal salt at a temperature ranging from 20 to 130°C, or
(ii) a Na2MoO4 precursor within a two step procedure comprising a first step using said Na2MoO4 precursor in presence of a solvent, in particular water buffered between 3 and 5, followed by a second step using the obtained Mo12(BP)4 in presence of a solvent, in particular water buffered between 3 and 5, BP, a M precursor at a temperature ranging from 20 to 90°C. The availability of the precursors is discussed below. With respect to the preparation of polyoxomolybdates complexes containing MoVI ions with bisphosphonates ligands, it is well known to the man skilled in the art to use a Na2MoO4 or a (ΝΗ4)6Mo7O24 precursor, which are besides commercially available. A solution of MoVI ions is simply prepared by dissolving the precursor in water. The pH value has to be controlled. The BP/Mo and M/Mo ratios are crucial parameters. The order of addition of reactants plays also a role. Temperature can be increased up to 130°C in case of poorly soluble BP. Addition of extra counter-cations (Na+, Rb ) can favor the crystallization.
BISPHOSPHONATES
Bisphosphonates that may be implemented in the framework of the present invention may be selected from all the classical ones as already disclosed in the literature.
Among known bisphosphonates, the following may be cited: etidronate, pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate and zoledronate.
Bisphosphonates in the framework of the present invention may be defined as compounds of general formula H2O3PC(OH)(R)PO3H2 (A)
wherein R represents
wherein
n is 1, 2 or 3,
R3 and R4 independently of each other are selected from a hydrogen atom, a halogen, a (C1-C4)alkyl group and a (C1-C4)alkoxy group, and
Q represents a phenyl group or a heteroaryl group, said phenyl and heteroaryl being optionally substituted with one to three substituents chosen from a (C1-C15)alkyl group, a halogen atom, a hydroxyl group, an OR1 group, a SRI group, a NR1R2 group or a CN group, and
Rl and R2 independently represent a hydrogen atom, a (C1-C6)alkyl or a -(CH2)XX, wherein x is 1, 2 or 3, and X has the same meaning as Q.
In the context of the present invention:
- The term "alkyl" as used herein refers to a linear or branched, saturated aliphatic hydrocarbon group. For instance a (C1-C6)alkyl group denotes a linear or branched carbon chain of 1 to 6 carbon atoms. Examples are, but are not limited to methyl, ethyl, propyl, isopropyl, butyl and methylbutyl.
- The term "heteroaryl" denotes a 5- or 6-membered aromatic ring comprising 1 or 2 heteroatoms,
- The term "heteroatom" is understood to mean nitrogen, oxygen or sulphur. Preferably, the heteroaryl comprises at least one nitrogen atom. According to a particular embodiment, the heteroaryl comprises only nitrogen as heteroatom(s). Thus, advantageously, the heteroaryl comprises from 1 to 4 nitrogen atoms, and preferably 1 or 2 nitrogen atoms.
Mention may be made of pyridine, thiazole, pyrrole, pyrazole, imidazole and triazole, and more particularly of imidazole.
In the context of the present invention, the term "heteroaryl" includes all the positional isomers.
Among the compounds of general formula (A), a first subgroup of compounds is formed from compounds for which R represents a (C1 -C8)alkyl group, optionally substituted by a NR1R2 group, with Rl and R2 having the same meaning as described above.
Among the compounds of general formula (I), a second subgroup of
compounds is formed from compounds for which R represents a group
wherein
n is 1 , 2 or 3,
R3 and R4 independently of each other are selected from a hydrogen atom, a halogen, a (C1-C4)alkyl group and a (C1-C4)alkoxy group, and
Q represents a phenyl group or a heteroaryl group, said phenyl and heteroaryl being optionally substituted with one to three substituents chosen from a (C1 -C15 alky 1 group, a halogen atom, a hydroxyl group, an OR1 group, a SRI group, a NR1R2 group or a CN group.
According to a particular embodiment, the bisphosphonate is defined as a
compound of formula (A) wherein R represents a
group in which n is 1 , R3
and R4 are hydrogen atoms and Q is group, optionally substituted by a
(C1-C15)alkyl group, in particular a (C1-C8) alkyl group.
According to an even more particular embodiment, the bisphosphonate is
defined as a compound of formula (A) wherein R represents a
group in which
n is 1 , R3 and R4 are hydrogen atoms and Q is a
group, where R5 represents a hydrogen atom or a (C1-C15)alkyl group, in particular a (C1-C8) alkyl group. This particular subgroups encompasses compound BPH-1222 as disclosed in Yifeng Xia et al, "a combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin", ScienceTranslationMedicine, Vol6, issue 263, 2014, 263ral61 , and illustrated in example 9 hereinafter (compound 9 of table 1 hereinafter).
According to a further particular embodiment, the present invention is directed to a compound of formula (I) for use in treating cancer, wherein BP is a compound of formula (A) wherein R represents a (C1 -C8)alkyl group, optionally substituted by a NR1R2
group or a where Rl and R2 independently represent a hydrogen
atom or a methylpyridine group, in particular a 2-methylpyridine group, and where R5 represents a hydrogen atom or a (C1-C8)alkyl group.
Structures and ligand abbreviations which may more particularly be implemented in the framework of the present invention are as follows:
The present invention relates to a polyoxomolybdate-bisphosphonate complex of formula (I) as defined above, for use in treating cancer, wherein x, y, z, t, n and M are as defined above and wherein the bisphosphonate ligand is chosen among alendronate, zolendronate, BPC8 NH2, AlePy, BPH-1222 and BPC9, and more particularly wherein M is Mn, Co, Cu, Zn or V, and even more preferably Mn, Cu, Co or V. According to a particular embodiment, M is Mn or Cu, Mn or Co, Mn or V, and even more particularly is Mn.
APPLICATION
The complexes as defined in the present invention are useful in the prevention and treatment of cancer.
According to the present invention, the term "preventing" or "prevention" means to reduce the risk of onset or slow the occurrence of a given phenomenon, namely, a cancer. Accordingly, the term "preventing" or "prevention" may encompass the "reduction of the likelihood of occurrence'" or the "reduction of the likelihood of progression" of a given phenomenon.
As detailed hereinafter in the experimental part, some of the complexes according to the present invention were tested to attest their activity against the human breast adenocarcinoma cell line MCF-7.
Moreover, cell growth inhibition was rescued by addition of geranylgeraniol, which reverses the effects of bisphosphonates on isoprenoid biosynthesis/protein prenylation. Overall, the results indicate an important role for both the heterometallic element as well as the bisphosphonate ligand in the mechanism of action of the most active compounds of the present invention.
The following type of cancer may more particularly be treated by the complex according to the present invention: bone cancer, colorectal cancer, pancreatic cancer, lung cancer including non-small cell lung cancer, breast cancer, large intestine cancer, biliary tract cancer, bladder cancer, gall bladder cancer, thyroid cancer, melanoma, liver cancer, uterine/cervical cancer, oesophageal cancer, kidney cancer, ovarian cancer, prostate cancer, head and neck cancer, and stomach cancer, etc.
Metastatic lesions, such as the ones associated with the previous types of cancers are also considered.
According to a particular embodiment, the present invention is more particularly directed to the prevention and/or treatment of bone, lung, large intestine, biliary tract, breast and pancreatic cancer.
According to another particular embodiment, the present invention is directed to the prevention and/or treatment of bone cancer (also referred herein as "bone tumor" or "malignant bone tumor"); which includes bone cancer selected from a group consisting of: primary bone tumors and secondary bone tumors.
Bone cancer may include any tumor of bones and cartilages, in particular any osseous and chondromatous neoplasmas, such as the ones selected from a group consisting of: bone sarcoma, osteoma, osteosarcoma, chondroma, osteochondroma, chondrosarcoma, ecchondroma, enchondroma, osteochondroma, chondromyxoid fibroma, ossifying fibroma, fibrosarcoma, chondroblastoma, multiple myeloma, adamatinoma and Ewing's sarcoma.
As shown in Example 11 on SK-ES-1 cell lines, the complex according to the invention is particularly suitable for treating a cancer associated with Human Ewing Sarcoma (anaplastic osteosarcoma).
According to a further particular embodiment, the present invention is more particularly directed to a method for treating patients suffering from a Ras-associated cancer, wherein said cancer is preferably associated with overactivated Ras.
In other words, in a preferred embodiment the cancer cells will harbor the ras oncogene.
According to a further more particular aspect of the present invention, it is directed to a method for treating patients suffering from a Ras-associated cancer, wherein said Ras protein is selected from HRAS, KRAS and NRAS.
The one skilled in the art may notably refer to the article of Miller et al. (2012, Frontiers in Genetics, Vol. 2, Article 100: 1-9).
According to some embodiments, the present invention relates to methods for treating patients suffering from a cancer wherein Ki-Ras comprises one or more mutations, which encompasses cancers wherein the Ki-Ras one or more mutations are present and are are selected in a group comprising CYS12, ASP12, VAL12, ALA12, SER12, ARG12, PHE12, ASP13, CYS13, ARG13, SER13, VAL13, ALA13, HIS61, ARG61 and ASP61. (See Miller et al, 2012, Supra).
For this purpose an effective amount of a said compound may be administered to a patient suffering from cancer.
PREFERRED COMPLEX
According to a preferred embodiment of the present invention, a complex according to the invention is chosen among:
- (1) Mo4O12Ale2Fe,
- (2) Mo4O12(BPC8NH2)2Fe,
- (3) Mo4O12(BPC9)2Fe,
- (4) Mo4O12Zol2Fe,
- (5) Mo4O12Ale2Mn (Mn(II)),
- (6) Mo4O12Zol2Mn (Mn(III)),
- (7) Mo12O32(AlePy)4Pt4Cl8,
The following complexes may be further cited as forming part of the present invention:
- (8) Mo4O12Ale2Mn (Mn(III)),
- (9) Mo4O12Zol2Mn (Mn(II)),
- (10) Mo4O12(BPH-1222)2Mn (Mn(II)),
- (11) Mo4O12(BPH-1222)2Mn (Mn(III)),
- (12) Mo4O12Zol2V (V(IV)), and
- (13) Mo4O12Zol2Ru (Ru(III)).
The chemical structures and status of some compounds of formula (I) of the invention are illustrated in the following Table 1.
Table 1
Therefore, the present invention extends to complexes (1) to (4) and (6) to (13). It more particularly relates to compounds (1), (2), (3), (4), (6), (7), (9) and (11), and even more particularly to compounds (6), (9) and (11).
The examples below of compositions according to the invention are given as illustrations with no limiting nature.
EXAMPLES
Infrared spectra were recorded on a Nicolet 6700 FT-IR spectrophotometer.
NMR measurements: 1H and 31P MAS NMR spectra were recorded on a Bruker AVANCE-500 spectrometer (Larmor frequencies of 500.135, 202.461, and 125.768 MHz, respectively) at room temperature (304 K) using a 3.2 mm MAS probe. The following conditions were used for recording the one- dimensional (ID) 1H MAS NMR spectra: 90° 1H pulse = 1.8 μs; delay time between scans = 1 s. 16 scans were collected for
each ID 1H MAS NMR spectrum. 31P MAS NMR spectra with high power proton decoupling were recorded with or without cross-polarization (CP). The following conditions were used for recording the spectrum with CP in the two-dimensional (2D) 31P{1H} CPMAS heteronuclear correlation (HETCOR) NMR experiment: the proton r.f. field strength for decoupling was 45 kHz; contact time was 2 msec at the Hartmann-Hahn match condition of 53 kHz; the delay time between scans was 1 sec. The direct polarization (DP) 31P{1H} MAS NMR spectra were recorded with 90° flip angle pulses of 2.2 μβεΰ duration and 21 sec recycle delay, which satisfied the 5 x
condition. In these experiments, high power proton decoupling (75 kHz) was used only during the acquisition time. 64 scans were collected for each ID 31P{1H} MAS NMR spectrum. For the 2D 31P{1H} CPMAS HETCOR NMR experiment a total of 64 h increments with 256 scans each were collected. The 31P{1H}-31P{1H} DQ-SQ MAS spectrum was obtained using the POSTC7 sequence with excitation and conversion periods of 0.8 msec. The 2D spectra were collected with 128 t\ increments of 50 and 16 transients each using the hypercomplex method. Presaturation pulses prior to the first pulse of the 2D sequence were used to reduce the recycle delay to 10 sec without saturation. The spin rate was 20 kHz for ID 1H MAS, ID 31P{1H} MAS, and 2D 31P{1H} CPMAS HETCOR, and 10 kHz for 2D 31P{1H}-31P{1H} DQ-SQ MAS. 1H chemical shifts were referenced with respect to external TMS, while 31P chemical shifts were referenced with respect to 85% H3PO4, with an accuracy of ± 0.4 ppm.
To a solution of Na2MoO4-2H20 (0.242 g, 1 mmol) in 10 mL of 1M
CH3COONH4/CH3COOH buffer was added Mn(OAc)3 2H20 (0.070 g, 0.26 mmol) and zoledronic acid (0.137 g, 0.5 mmol). The solution was stirred for 5 min then NH3 (33% in water) was added dropwise to pH = 7.5. The solution was left to evaporate and was filtered after 24 h in order to remove a pink precipitate. EDX measurements and IR spectroscopy indicated that the precipitate was a manganese BP complex that did not contain molybdenum. Greyish crystals of the title compound appeared after three days.
Yield: 0.080 g (21% based on Mo). Anal. Calc. (found) for C1oH52MnMo4N9O36P4 (M.W. = 1437 g mol-1): C 8.36 (8.88), H 3.65 (3.90), N 8.77 (8.78). IR (FTR): v (cm-1) = 1575(m), 1546 (w), 142 l(s), 1288 (w), 1136(s), 1112(sh), 1045(s), 1018(sh), 973(m), 915(s), 888(s), 790(s), 699(m), 656(m), 619(w), 560(w), 529(m).
1)
To a solution in 10 mL of water
was added H5Ale (0.697 g, 2.80 mmol) and FeCl3-6H20 (0.378 g, 1.4 mmol). The solution was stirred for 5 min then NH3 (33 > in water) was added drop wise to pH = 6.0. The solution was then stirred for 40 min at 90 °C until clear. After cooling to room temperature, a fine powder was filtered off and the solution left to evaporate. Yellow crystals appeared after 30 min and were collected after two days.
Yield: 1.20 g (61 % based on Mo). Anal. Calc. (found) for C8H6oFeMo4N7O37P4
(M.W. = 1410 g mol-1): C 6.81 (6.89), H 4.29 (4.15), N 6.95 (6.99), P 8.79 (8.68), Mo 27.21 (26.99), Fe 3.96 (3.94). IR (FTR): v (cm 1) = 1602(sh), 1421(vs), 1130(s), 1039(sh), 858(s), 802(s), 690(w), 641(m), 574(w), 510(m), 481(vw).
A mixture of (NH4)6Mo7024-4H20 (0.200 g, 0.16 mmol), FeCl3.6H2O (70 mg, 0.25 mmol) and in 20 mL of water was stirred and the
pH adjusted to 7.5 by addition of NH3 (33%> solution). The mixture was heated to 90°C for 1 h and then cooled to room temperature. The resulting mixture was filtered and the filtrate left to slowly evaporate. After two weeks, yellow crystals were collected by filtration.
Yield: 0.145 g (34% based on Mo). Anal. Calc. (found) for C16H74FeMo4N7O36P4 (M.W. = 1504 g mol-1): C 12.77 (12.71), H 4.95 (4.66), N 6.51 (6.17), Fe 3.71 (3.70), Mo 25.51 (25.82), P 8.24 (8.38). IR (FTR): v (cm-1) = 1615(sh), 1417(s), 1117(s), 1041(vs), 1018(vs), 940(w), 905(s), 860(s), 789(s), 702(s), 653(s), 573(s), 513(s), 484(s).
Table 1)
A mixture of (NH4)6Mo7024.4H20 (0.248 g, 0.20 mmol), FeCl3.6H20 (0.095 g,
0.35 mmol) and Na2H3(BPC9) (0.258 g, 0.74 mmol) in 5 mL of 1 M CH3COONH4/CH3COOH buffer was stirred and the pH adjusted to 7.5 by addition of NH3 (33% solution). The mixture was then sealed in a 23 mL Teflon-lined stainless steel reactor and heated to 130°C over a period of 4 h, kept at 130°C for 20 h, then cooled to room temperature over a period of 36 h. The resulting mixture was filtered and the filtrate left to slowly evaporate. After five days, yellow crystals were collected by filtration.
Yield: 0.075 g (53% based on Mo). Anal. Calc. (found) for
C 14.04 (13.98), H 5.30 (5.38), N 5.91 (6.22), Fe 3.63 (3.61), Mo 24.92 (25.08), P 8.05 (8.01), Na 0.75 (0.65). IR (FTR) : v (cm-1) = 1635(w), 1419(s), 1115(m), 1036(s), 1009(s), 913(s), 892(s), 860(m), 794(s), 694(s), 667(w), 650(s), 571(vs), 509(s), 483(s).
Table 1)
A mixture of (NH4)6Mo7024.4H20 (0.248 g, 0.20 mmol), FeCl3.6H20 (0.095 g, 0.35 mmol) and zoledronic acid (0.201 g, 0.77 mmol) in 5 mL of 1 M CH3COONH4/CH3COOH buffer was stirred and the pH adjusted to 6 by addition of NH3 (33% solution). The mixture was sealed in a 23 mL Teflon-lined stainless steel reactor and heated to 130°C over a period of 4 h, kept at 130°C for 20 h, then cooled to room temperature over a period of 36 h. Yellow crystals were collected by filtration and were washed with water.
Yield: 0.315 g (67% based on Mo). Anal. Calc. (found) for C10H42FeMo4N9O3iP4 (M.W. = 1348 g mol-1): C 8.92 (8.87), H 3.14 (3.09), N 9.35 (9.36), Mo 28.46 (28.36), Fe 4.14 (4.21), P 9.19 (9.20). IR (FTR) : v (cm-1) = 1652(w), 1575(m), 1545(m), 1429(vs), 1394(s), 1313(w), 1284(m), 1138(s), 1118(s), 1042(vs), 977(s), 948(m), 914(m), 869(s), 783(s), 708(s), 676(s), 621(s), 576(s), 516(s), 481(s).
Compound 7 in Table 1)
To a solution of Na2MoO4.2H20 (0.582 g, 2.4 mmol) in 40 mL of water was added Na2H3(AlePy) (0.308 g, 0.70 mmol) and the pH was adjusted to 3 using a 2 M solution of HCl. The solution was stirred for 1 h at 90°C, cooled to room temperature and slowly evaporated. White crystals (0.240 g, yield 34% based on Mo) were filtered off after
(13.1 1), H 3.12 (3.02), Mo 32.39 (32.41), N 3.15 (3.01), Na 2.59 (2.88), P 6.88 (7.04). IR (FTR): v (cm-1) = 1623(m), 1529(w), 145 l(m), 1145(sh), 1126(s), 1056(sh), 1026(s), 965(w), 917(m), 874(s), 794(m), 760(m), 682(sh), 647(m), 541(m), 520(m), 489(m), 401(m).
To a suspension of Mo12(AlePy)4 (0.12 g, 0.033 mmol) in 3 mL of water was added a solution of Pt(DMSO)2Cl2 (0.078 g, 0.185 mmol) in 2 mL of water heated to 60°C and the pH was adjusted to 3 using 2 M HCl. The solution was stirred for 1 h at 90 °C, cooled to room temperature and NaCl (0.500 g, 8.55 mmol) added. The solution was stirred for 1 h. A beige precipitate was collected by filtration (0.055 g, yield 35%> based on
10.02 (11.02), H 2.44 (2.45), CI 5.91 (3.55), Mo 24.00 (23.42), N 2.33 (2.33), Na 3.83 (4.04), P 5.17 (5.26), Pt 16.27 (16.00). IR (FTR) : v (cm 1) = 1612(m), 1489(w), 1425(m), 1121(s), 1024(s), 922(sh), 883(s), 789(m), 767(m), 676(sh), 652(m), 545(m).
Example 6.3: determination of the structure of
Solid State NMR Spectroscopy
Since it was not possible to determine the structure of the Mo12(AlePy)4Pt complex by using crystallography, it was determined by the comparison of the solid state
NMR spectra of Mo12(AlePy)4 (which is essentially insoluble in water) and Mo12 AlePy)4Pt4 using one and two-dimensional magic-angle sample spinning techniques. The ID 31P{1H} MAS NMR spectrum of Mo12(AlePy)4 exhibits four resolved lines, at 18.1 (23%), 20.0 (23%), 25.3 (27%), and 26.4 ppm (27%), in agreement with the four crystallographic P sites. The 2D 31P{1H}-31P{1H} DQ-SQ correlation experiment shows strong dipolar coupling between the resonances at 18.1 and 26.4 ppm, as well as those at 20.0 and 25.3 ppm, consistent with two distinct AlePy environments, similar to the observation of two pairs of signals in the range 26-27 and 29-33 ppm observed for alendronate in [(Mo202X2(H20))4(Ale)4]8-, where X = O or S (H. El Moll et al Dalton Trans. 2012, 41, 9955). The MAS NMR spectrum of the platinum complex Mo12(AlePy)4Pt4 shows two signals, centered at ca. 21 and 25 ppm, about the same as observed with Mo12(AlePy)4, but with obvious line-broadening. The broadening could be due either to the low crystallinity in Mo12(AlePy)4Pt4 and/or, a dynamic disorder, since we also observe a much less efficient CP transfer in CPMAS experiments when compared with Mo12(AlePy)4 .
The 1H MAS spectrum of Mo12(AlePy)4 consists of a dominant resonance at 4.2 ppm due to water molecules, with a very small shoulder at ca. 2 ppm, and two other signals, centred at ~ 8 and 18.4 ppm. The resonances around 2 and 8 ppm are assigned to methylene and aromatic protons of the AlePy ligands. The signal at ca. 18 ppm arises from acidic protons and the results of a 2D 31P{1H} HETCOR experiment clearly indicates close proximity between this/these proton/s and the phosphorus responsible for the resonance at 20 ppm. A close inspection of the structure indicates that of the four phosphonate groups (PI, P2, P3 and P4) only one, P2, is involved in a strong hydrogen bond interaction, via its terminal P=0 group (Figure 2). More specifically, P2 has a 1.7 A intermolecular N- Η···0=Ρ hydrogen bond between the protonated pyridine group (N24-H24) and the terminal oxygen (029) of the phosphonate P2 in the crystal structure. From these observations the 31P NMR signals was thus assigned as follows: Pl/P2=25 ppm/20 ppm and P3/P4=18 ppm/26 ppm, where PI and P4 correspond to (P-(OMo)3) and P2 and P3 correspond to (0=P-(OMo)2). The signal at 18.4 ppm in the 1H spectrum thus corresponds to the pyridinium proton of the AlePy ligand. The 1H MAS spectrum of the Pt complex Mo12(AlePy)4Pt4 is very similar to that of Mo12(AlePy)4, the only difference being the
absence of the resonance at 18.4 ppm, clearly, a consequence of the complexation of the pyridine to Pt.
Example 7: X-ray crystallography measurement
Data collection was carried out by using a Siemens SMART three-circle diffractometer for Mo4Ale2Fe and Mo4(BPC9)2Fe and by using a Bruker Nonius X8 APEX 2 diffractometer for Mo2Ale2Mn, Mo4(BPC8NH2)2Fe and Mo12(AlePy)4. Both were equipped with a CCD bi-dimensional detector using the monochromatized wavelength λ(Μο Κα) = 0.71073 A. Absorption correction was based on multiple and symmetry-equivalent reflections in the data set using the SADABS program (G. M. Sheldrick, SADABS; program for scaling and correction of area detector data, University of Gottingen, Germany, 1997) based on the method of Blessing (R. Blessing, Acta Crystallogr. 1995, A51, 33). The structures were solved by direct methods and refined by full-matrix least-squares using the SHELX-TL package (G. M. Sheldrick, SHELX-TL version 5.03, Software Package for the Crystal Structure Determination, Siemens Analytical X-ray Instrument Division: Madison, WI USA, 1994). In all structures there are small discrepancies between the formulae determined by elemental analysis and those deduced from the crystallographic atom list because of the difficulty in locating all disordered water molecules (and sometimes the counter-cations), a common feature found in other polyoxometalate structural investigations (See for example a) M. Sadakane, M. H. Dickman, M. T. Pope, Angew. Chem. Int. Ed. 2000, 39, 2914; b) C. Zhang, R. C. Howell, K. B. Scotland, F. G. Perez, L. Torado, L. C. Francesconi Inorg. Chem. 2004, 43, 7691; c) Z. Zhang, Y. Qi, C. Qin, Y. Li, E. Wang, X. Wang, Z. Su, L. Xu, Inorg. Chem. 2007, 46, 8162; d) N. Belai, M. T. Pope, Chem. Commun. 2005, 46, 5760). In the structures of Mo4Ale2Fe and Mo4(BPC9)2Fe, NH4 + and H20 could not be distinguished based on the observed electron densities; therefore, all the positions were labelled O and assigned the oxygen atomic diffusion factor. Crystallographic data are given in Table 2.
Table 2
Compound 9 in Table 1)
NH4PF6 (0.200 g, 1.2 mmol) and ascorbic acid (0.150 g, 0.85 mmol) were added to a suspension of (NH4)5[(Mo2O6)2(O3PC(CH2C3H4N2)(O)PO3)2Mn].10H2O (0.190 g, 0.13 mmol) in 30 mL of MeOH. The solution was stirred for 6 hours and was filtrated. The pale yellow solid was washed with MeOH. Yield 0.129 g (68%). Anal. Calc. (found) for
(7.98), IR (FTIR) : v (cm-1) = 1579(m), 1546 (w), 1418(s), 1286 (w), 1137(s), 1112(sh), 1047(s), 1018(sh), 975(m), 911(s), 887(s), 786(s), 699(m), 659(m), 619(w), 561(w), 529(m), 485(w). SQUID measurements confirm the +2 oxidation state of the Mn ions.
The H2P(V salt of BPH-1222, [BPH-1222]H2PO4, was synthesized following the synthesis reported in Y. Xia et al. Sci. Transl. Med. 2014, 6, 263ral61. The H2PO4- salt was transformed in the lithium salt Li2[BPH-1222] by addition of LiOH. [BPH- 1222]H2PO4 (0.500 g, 1 mmol) was dissolved in 10 mL of water. 1M LiOH was then added until pH 7. The solution was stirred for 24h. The solid was collected by filtration and washed with MeOH.
Na2MoO4 (0.197 g, 0.821 mmol) was dissolved in 5 mL of 1 M NH4OAc/HOAc. 1M HCl was added dropwise to a suspension of Li2[BPH-1222] (0.027 g, 0.068 mmol) in 3 mL of water until dissolution. This solution was added to the molybdate solution. Solid Mn(OAc)3.2H20 (0.018 g, 0.068 mmol) was added and the pH adjusted to 5.8 using NH3 33%). The solution was stirred for two hours at room temperature and filtered. A bright orange precipitate which does not contain the BP ligand was removed and the filtrate left to evaporate. Pink platelets were collected by filtration three days later. Yield 0.011 g (20% based on BPH-1222). Anal. Calc. (found) for
(5.80). IR (FTIR) : v (cm 1) = 1636(w), 1559(m), 1415 (s), 1130(m), 1081(m), 1045(s),
979(w), 914(m), 876(s), 796(w), 736(w), 686(m), 620(m), 528(w), 484(w). EDX measurements confirm the Mo/P and Mo/Mn ratios.
Example 10: Magnetic studies
Magnetic susceptibility measurements were carried out with a Quantum Design
SQUID Magnetometer with an applied field of 1000 Oe for Mo4Ale2Mn and 10000 Oe for Mo4Zol2Mn using powder samples pressed into pellets to magnetic ordering of the crystallites. The independence of the susceptibility value with regard to the applied field was checked at room temperature. The susceptibility data were corrected for the diamagnetic contributions as deduced by using Pascal's constant tables. All the magnetic data have been simulated using a FORTRAN program.
Magnetic susceptibility measurements were carried out to deduce the Mn oxidation state in the Mo4Ale2Mn and Mo4Zol2Mn complexes, the latter being of particular interest since, as discussed below, it had the most potent activity in tumor cell growth inhibition. The curve for Mo4Ale2Mn is shown in Figure 3a. The
product is constant in the 250 - 30 K temperature range, with a value of 4.235 cm3
mol-1 K at 250 K, the theoretical value being 4.375 cm3 mol-1 K for a mononuclear
high-spin Mn11 complex (S = 5/2), assuming g = 2.0. Beyond 30 K, due to single ion- anisotropy, the curve continuously decreases, reaching 3.875 cm3 mol-1 K at 2 K. The
magnetization was thus measured at 3, 4, 6 and 8 K as a function of the magnetic field. As can shown in Figure 3b, the data can be well fit by using D = +0.97 cm-1 and g = 1.97 in the spin Hamiltonian:
where β is the Bohr magneton, H the magnetic field, g the spectroscopic splitting factor and D the axial zero-field splitting parameter (R = 1.4 10-4)(R = [∑(MCEFC-
The \D\ value is higher than those usually determined with six-coordinated Mn11 complexes (for example C. Duboc et al. Chem. Eur. J. 2008, 14, 6498). However, it is known that polyoxometalate ligands can induce a strong magnetic anisotropy, as exemplified by the D value of +1.46 cm-1 found in the Mn11 complex
(C. Pichon et al. Inorg. Chem. 2007, 46, 7710). The
curve for Mo4Zol2Mn Figure 3 a again shows that the product is constant in the 250 -
30 K temperature range but with a value of 3.05 cm3 mol-1 K. This value is in good
agreement with the theoretical value of 3.00 cm3 mol-1 K calculated considering g =
2.0 for a mononuclear S = 2 Mnin complex. Fits of the M = f(H) curves (Figure 3c) at T = 3, 4, 6 and 8 K lead to D = +3.20 cm-1 and g = 2.02 (R = 4.6 10-4).34 Both the D and g values fall within the range of those determined for mononuclear Mnin complexes(for example C. Duboc et al, J. Phys. Chem. A. 2010, 114, 10750). Also, the curves
of the Mo4Α1β2Μη and Mo4Z0I2M11 complexes can be fitted (Figure 3a) using the parameters deduced from the magnetization data (R = 3.2 10-5 and 1.21 10-4, respectively). These results are thus in agreement with the bond valence sum calculations noted above, confirming that Mo4Α1β2Μη contains a Mn11 center while Mo4Z0I2M11 contains a Mnm.
Example 11: Biological data
Example 11.1 : Cell-growth inhibition assays
Human tumor cell lines MCF-7 (breast adenocarcinoma were obtained from the National Cancer Institute and maintained at 100% humidity and 5% C02 at 37 °C. Cell lines were cultured in RPMI-1640 medium supplemented with 2 mM L-glutamine and 10%) fetal bovine serum (Gibco, Grand Island, NY) at 37°C in a 5% C02 atmosphere with 100%) humidity. Compound stock solutions were typically prepared in water at a concentration of 0.04 M. A broth microdilution method was used to determine the bisphosphonate growth inhibition IC50 values. Compounds were half log serial diluted using cell culture media into 96-well TC-treated round bottom plates (Corning Inc., Corning, NY) typically from 1264 μΜ to 40 nM, but in some cases compounds were run over a larger concentration range to enable accurate IC50 determinations. Cells were plated at a density of 5000 cells/well. Cells were then incubated under the same culture conditions for 4 days at which time an MTT ((3-(4,5-dimethylthi-azole-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation assay (ATCC, Manassas, VA) was performed to obtain dose response curves. Briefly, cells were incubated for 2 h under culture conditions with the tetrazolium salt, lysed with detergent, incubated overnight, protected from light at room temperature. The absorbance at 600 nm was read the following day using a SpectraMax Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA). The compound concentration for 50% growth inhibition values (IC50) were obtained by fitting absorbance data to a rectangular hyperbolic function: where / is the percent
inhibition, 7max = 100% inhibition and C is the concentration of the inhibitor, using GraphPad PRISM 3.0 software for windows (Graphpad Software Inc., San Diego, CA).
Results are gathered in table 3 hereinafter. The results are shown on a molar basis (IC50 values, in μΜ) as well as on a per-bisphosphonate basis, which is more logical when comparisons are to be made with the pure bisphosphonates.
Both the heteroatom as well as the bisphosphonate are having effects on cell growth inhibition, although addition of Mn(II)Cl2 alone has essentially no effect (IC50-740 μΜ) on cell growth.
Such results may be compared to the results as obtained in Hani El Moll et al., "polyoxometalates functionalized by bisphosphonate ligands: synthesis, structural, magnetic, and spectroscopic characterizations and activity on tumor cell lines", Inorg. Chem. 2012, 51, 7921-7931. Indeed said document discloses the same activity for polyoxometalates functionalized by bisphosphonate ligands which do not bear heteroatoms. The results are re roduced in the followin table 4.
Indeed, although the oxidation state in both compounds are different, the benefit of adding an heteroelement is clearly visible for the tested compounds (Mo4Ale2Mn is far better than Mo6(Ale)2, Mo4Zol2Mn is slightly better than Mo6(Zol)2).
Example 1 1.2: Evidence for significant targeting of protein prenylation pathways
Addition of geranylgeraniol (GGOH) was tested on Mo4Zol2Mn.
Protocol Cell growth "rescue" experiments with geranylgeraniol were carried out as described previously, and namely in Y. Zhang, et al J. Am. Chem. Soc. 2009, 131 , 51.
An increase in the IC50 indicates a direct role for the bisphosphonate moiety in cell growth inhibition.
Results are athered in table 5 hereinafter.
There is a major rescue with geranylgeraniol, just as found with zoledronate acting alone. These results indicate that there may be a significant contribution to cell growth inhibition from the presence of Mnni.
Example 11.3:
Experimental section (from Y. Zhang et al. J. Am. Chem. Soc. 2009, 131,
5153)
In Vivo Tumor Model
Experiments were carried out basically as described in Kubo et al. (Kubo, T.; Shimose, S.; Matsuo, T.; Tanaka, K.; Yasunaga, Y.; Sakai, A.; Ochi, M. J. Orthop. Res. 2006, 24, 1138-44). Xenografts of human SK-ES-1 cells were initiated by subcutaneous injections of 1.5 x 107 cells into the right flank of four 6-week old athymic nude mice (CLEA, Tokyo, Japan). The mice received daily intraperitoneal injections of bisphosphonate Μο4Ζο12Μη(ΠΙ) as prepared in example 1 (5 μg, for 30 days), or physiological saline. The smallest and largest diameters of tumors, and the body weights, were measured weekly. Tumor volumes were calculated using the following formula: volume (mm3) ) (smallest diameter)2 x (largest diameter)/2. All animal experiments were conducted according to the guidelines of the Institutional Animal Care and Use Committee, and the protocol was approved by the Ethics Committee for Experimental Animals of Hiroshima University. Statistical significance was determined by one-way ANOVA and Fisher's PLSD method, using Statcel (OMS Ltd., Saitama, Japan); p < 0.05 was considered to be significant.
The calculation for the tumor volume is as follows, in accordance with the scheme represented in figure 4
Results: The results are gathered in table 6 as follows
Conclusion: Mo4Zol2Mn had statistically significant effect to suppress sarcoma growth thus showing its therapeutic anti-cancer activity, in particular via local injection.
The present invention is also related to the use of at least a compound chosen among a compound of any one of formula (I), (la) or (lb) as defined above, and compounds (1) to (13) as defined above, for the manufacture of a pharmaceutical composition intended for the treatment of cancer.
The present invention also encompasses pharmaceutical compositions comprising at least a compound selected from the complexes of formulae (la) with the exclusion of complexes Mo4O12Eti2Mn (Mn(II)), Mo4O12Ale2Mn (Mn(II)), Mo4O12Ale2V (V(IV)), Mo4O12Eti2Fe (Fe(III)) and Mo4O12Eti2V (V(IV)) and (lb) as defined above and compounds (1) to (4) and (6) to (13) as defined above or any pharmaceutically acceptable salt thereof.
The present invention in particular encompasses pharmaceutical compositions comprising at least a compound selected from compounds (1), (2), (3), (4), (6), (7), (9) and (1 1), in particular selected from compounds (6), (9) and (1 1).
Thus, these pharmaceutical compositions contain an effective amount of said compound, and one or more pharmaceutical excipients.
The aforementioned excipients are selected according to the dosage form and the desired mode of administration.
The complexes as defined in the present invention may be suitable for any route of administration. Accordingly, and in a non-exhaustive manner, the complexes are suitable for oral administration, enteral administration, parenteral administration, topical administration, and/or inhalation.
Accordingly, a route of administration may be selected from the group consisting of: epidural, intracerebral, intracerebroventricular, subcutaneous, transdermal, intradermal, sublingual, buccal, extra-amniotic, nasal, intra-arterial, intra-venous, intraarticular, intra-cardiac, intra-carvenous, intra-lesional, intra-muscular, intra-ocular, intra-
osseous, intra-peritoneal, intra-pulmonary, intra-thecal, intra-uterine, intra-vaginal, intravesical, intra-vitreal, sublingual administration, and trans-mucosal administration.
According to exemplary embodiments, the complexes as defined in the present invention are suitable for parenteral and/or intraperitoneral administration.
In this context they can be present in any pharmaceutical form which is suitable for enteral, parenteral and/or intraperitoneral administration, in association with appropriate excipients, for example in the form of plain or coated tablets, hard gelatine, soft shell capsules and other capsules, suppositories, or drinkable, such as suspensions, syrups, or injectable solutions or suspensions, in doses which enable the daily administration of from 0.1 to 1000 mg of active substance.
The present invention further relates to a method of treatment of patients suffering from cancer, which comprises at least a step of administration to a patient suffering thereof of an effective amount of a compound of any one of formulae (I), (la) or (lb) as defined above and (1) to (13).
Claims
1. Polyoxomolybdate-bisphosphonate complex containing a bisphosphonate ligand, wherein it further contains a heterometallic ion different from molybdenum, for use in treating cancer, said heterometallic ion being a 3d, 4d or 5d transition metallic ion, in particular a 3d or 4d transition metallic ion and even more particularly a 3d transition metallic ion.
2. A polyoxomolybdate-bisphosphonate complex as defined in claim 1, for use in treating cancer, having the following formula (I)
wherein
x, y, z, t, r and n are independent integers,
2 < x < 12,
y > x, and y ranges from 4 to 40,
z < x, and z ranges from 2 to 8,
t < x and t ranges from 1 to 10,
r ranges from 0 to 8,
n represents an integer ranging from 2 to 16,
M represents a 3d transition metal ion selected from Mn, Fe, Cu, Zn, V and Co or a 4d or 5d transition metal like Ru or Pt, and preferably M represents Mn, Co, Cu, Zn or V, and even more preferably Mn, Cu, Co or V, alternatively Mn or Cu, alternatively Mn or Co, alternatively Mn or V, and even more particularly represents Mn,
X represents an halogen atom or a water molecule, and
BP represents a bisphosphonate.
3. A polyoxomolybdate-bisphosphonate complex as defined in claim 1 or 2, for use in treating cancer, wherein the polyoxometalate-bisphosphonate complex contains Mo4 or Mo 12 clusters and in particular a Mo4 cluster.
4. A polyoxomolybdate-bisphosphonate complex as defined in anyone of the preceding claims, for use in treating cancer, wherein the bisphosphonate has the following formula H2O3PC(OH)(R)P03H2 (A)
wherein R represents
- a (C1-C8)alkyl group, optionally substituted by a NR1R2 group, or
- a
group
wherein
n is 1 , 2 or 3,
R3 and R4 independently of each other are selected from a hydrogen atom, a halogen, a (C1-C4)alkyl group and a (C1-C4)alkoxy group, and
Q represents a phenyl group or a heteroaryl group, said phenyl and heteroaryl being optionally substituted with one to three substituents chosen from a (C1 -Chalky 1 group, a halogen atom, a hydroxyl group, an ORl group, a SRI group, a NR1R2 group or a CN group, and
Rl and R2 independently represent a hydrogen atom, a (C1-C6)alkyl or a -(CH2)XX, wherein x is 1 , 2 or 3, and X has the same meaning as Q as defined above.
5. A polyoxomolybdate-bisphosphonate complex as defined in the preceding claim, for use in treating cancer, wherein R represents a (C1-C8)alkyl group, optionally
substituted by a NR1R2 group or a , where Rl and R2 independently
represent a hydrogen atom or a methylpyridine group, in particular a 2-methylpyridine group, and where R5 represents a hydrogen atom or a (C1-C8)alkyl group.
6. A polyoxomolybdate-bisphosphonate complex as defined in anyone of the preceding claims, for use in treating cancer, wherein the bisphosphonate ligand is chosen among alendronate, zolendronate, BPC8NH2, AlePy, BPH-1222 and BPC9, and more particularly wherein M is Mn.
7. A polyoxomolybdate-bisphosphonate complex as defined in claim 4, for use in treating cancer, wherein the bisphosphonate ligand is defined as a compound of
formula (A) wherein R represents a group in which n is 1 , R3 and R4 are
hydrogen atoms and Q is a group, where R5 represents a hydrogen atom or a (C1-C15)alkyl group.
8. A polyoxomolybdate-bisphosphonate complex as defined in anyone of the preceding claims, for use in treating cancer, wherein the heterometallic ion different from molybdenum is Mn, said heterometallic ion being a 3d, 4d or 5d transition metallic ion, in particular a 3d or 4d transition metallic ion and even more particularly a 3d transition metallic ion.
9. A polyoxomolybdate-bisphosphonate complex as defined in anyone of the preceding claims, for use in treating cancer, wherein it is selected from (1) Mo40i2Ale2Fe, (2) Mo4O12 (BPC8NH2)2Fe, (3) Mo4O12(BPC9)2Fe, (4) Mo4O12Zol2Fe, (5) Mo4O12Ale2Mn (Mn(II)), (6) Mo4O12Zol2Mn (Mn(III)), (7) Mo12032(AlePy)4Pt4Cl8, (8) Mo4O12Ale2Mn (Mn(III)), (9) Mo4O12Zol2Mn (Mn(II)), (10) Mo4O12(BPH-1222)2Mn (Mn(II)), (11) Mo4O12(BPH-1222)2Mn (Mn(III)), (12) Mo4O12Zol2V (V(IV)) and (13) Mo4O12Zol2Ru (Ru(III)), and more particularly from Mo4O12Ale2Fe, (2) Mo4O12(BPC8NH2)2Fe, (3) Mo4O12(BPC9)2Fe, (4) Mo4O12Zol2Fe, (5) Mo4O12Ale2Mn (Mn(II)), (6) Mo4O12Zol2Mn (Mn(III)) and (7) Mo12032(AlePy)4Pt4Cl8, and in particular selected from compounds (1), (2), (3), (4), (6), (7), (9) and (11), and more particularly selected from compounds (6), (9) and (11).
10. A polyoxomolybdate-bisphosphonate complex for use in treating cancer, according to anyone of the preceding claim, wherein the cancer is selected from colorectal cancer, bone cancer, pancreatic cancer, lung cancer including non-small cell lung cancer, breast cancer, large intestine cancer, biliary tract cancer, bladder cancer, gall bladder cancer, thyroid cancer, melanoma, liver cancer, uterine/cervical cancer, oesophageal cancer, kidney cancer, ovarian cancer, prostate cancer, head and neck cancer, and stomach cancer, and more particularly from lung, breast, large intestine, biliary tract and pancreatic cancer.
11. A polyoxomolybdate-bisphosphonate complex having the following formula (la)
wherein
BP is a bisphosphonate as defined in claim 4 or 5, and
M represents a 3d transition metal ion selected from Mn, Pt, Fe, Cu, Zn, V and Co or a 4d transition metal like Ru, and in particular M represents Mn, V or Ru, and preferably M represents Mn, Co, Cu, Zn or V, and even more preferably Mn, Cu, Co or V, alternatively Mn or Cu, alternatively Mn or Co, alternatively Mn or V, and even more particularly represents Mn,
with the exclusion of compounds Mo40i2Eti2Mn (Mn(II)), Mo4Oι2Α1e2Μη (Mn(II)), Mo4O12Ale2V (V(IV)), Mo4O12Eti2Fe (Fe(III)) and Mo4O12Eti2V (V(IV)) or
the following formula (lb)
wherein BP is a bisphosphonate as defined in anyone of claims 4 to 7,
X represents a halogen atom or a water molecule, and
M represents a 3d transition metal ion selected from Mn, Fe, Cu, Zn, V and Co or a 4d or 5d transition metal like Ru or Pt, and in particular M represents Mn, V or Ru, and preferably M represents Mn, Co, Cu, Zn or V, and even more preferably Mn, Cu, Co or V, alternatively Mn or Cu, alternatively Mn or Co, alternatively Mn or V, and even more particularly represents Mn.
12. A polyoxomolybdate-bisphosphonate complex selected from Mo4O12Ale2Fe (1), Mo4O12(BPC8NH2)2Fe (2), Mo4O12(BPC9)2Fe (3), Mo4O12Zol2Fe (4), Mo4O12Zol2Mn (Mn(III)) (6), Mo12032(AlePy)4Pt4C18 (7), Mo4O12Ale2Mn (Mn(III)) (8), Mo4O12Zol2Mn (Mn(II)) (9), Mo4O12(BPH-1222)2Mn (Mn(II)) (10), Mo4O12(BPH-1222)2Mn (Mn(III)) (11), Mo4O12Zol2V (V(IV)) (12) and Mo4O12Zol2Ru (Ru(III)) (13), and more particularly selected from Mo4O12(BPH-1222)2Mn (Mn(III)), Mo4O12Zol2Mn (Mn(III)) and Mo4O12Zol2Mn (Mn(II)).
13. A pharmaceutical composition comprising a polyoxomolybdate as defined in anyone of claims 11 and 12.
14. A synthetic preparation process for obtaining a polyoxomolybdate as defined in anyone of claims 11 and 12, consisting in reacting
(i) a precursor selected from Na2MoO 4 and (ΝΗ4)6Mo7O24 within a one-pot procedure in presence of a solvent, in particular water buffered between 3 and 8, BP, a M metal salt at a temperature ranging from 20 to 130°C, or
(ii) a Na2MoO4 precursor within a two step procedure comprising a first step using said Na2MoO4 precursor in presence of a solvent, in particular water buffered between 3 and 5, followed by a second step using the obtained Mo12(BP)4 in presence of a solvent, in particular water buffered between 3 and 5, BP, a M precursor at a temperature ranging from 20 to 100°C.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305812.8 | 2015-05-28 | ||
| EP15305812.8A EP3098228A1 (en) | 2015-05-28 | 2015-05-28 | Polyoxomolybdate-bisphosphonate complex containing a heterometallic ion different from molybdenum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016189109A1 true WO2016189109A1 (en) | 2016-12-01 |
Family
ID=53269419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2016/061948 WO2016189109A1 (en) | 2015-05-28 | 2016-05-26 | Polyoxomolybdate-bisphosphonate complex containing a heterometallic ion different from molybdenum |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3098228A1 (en) |
| WO (1) | WO2016189109A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111138498A (en) * | 2019-12-27 | 2020-05-12 | 湖北工业大学 | Application of disubstituted aromatic acid modified Anderson polyacid as coxsackie virus inhibitor |
| CN111886221A (en) * | 2018-03-16 | 2020-11-03 | 阿科玛法国公司 | Synthesis method of azo compound |
-
2015
- 2015-05-28 EP EP15305812.8A patent/EP3098228A1/en not_active Withdrawn
-
2016
- 2016-05-26 WO PCT/EP2016/061948 patent/WO2016189109A1/en active Application Filing
Non-Patent Citations (41)
| Title |
|---|
| A. BANERJEE ET AL., CHEM. SOC. REV., vol. 41, 2012, pages 7590 |
| A. DOLBECQ ET AL., CHEM. COMMUN., vol. 48, 2012, pages 8299 |
| A. DOLBECQ ET AL.: "Molybdenum bisphosphonates with Cr(III) or Mn(III) ions", J. CLUST. SCI., vol. 25, 2014, pages 795 |
| A. SAAD ET AL., J. CLUST. SCI., vol. 25, 2014, pages 795 |
| A. STACHNIK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 111, 2014, pages 17995 |
| ALI SAAD ET AL., J. CLUST SCI, vol. 25, 2014, pages 795 - 809 |
| ALI SAAD ET AL: "Polyoxomolybdate Bisphosphonate Heterometallic Complexes: Synthesis, Structure, and Activity on a Breast Cancer Cell Line", CHEMISTRY - A EUROPEAN JOURNAL., vol. 21, no. 29, 15 June 2015 (2015-06-15), WEINHEIM, DE, pages 10537 - 10547, XP055225658, ISSN: 0947-6539, DOI: 10.1002/chem.201406565 * |
| B. HASENKNOPF: "polyoxometalates: introduction to a class of inorganic compounds and their biomedical applications", FRONTIERS IN BIOSCIENCE, vol. 10, 1 January 2005 (2005-01-01), pages 275 - 287 |
| C. DUBOC ET AL., CHEM. EUR. J., vol. 14, 2008, pages 6498 |
| C. DUBOC ET AL., J. PHYS. CHEM. A., vol. 114, 2010, pages 10750 |
| C. PICHON ET AL., INORG. CHEM., vol. 46, 2007, pages 7710 |
| C. ZHANG; R. C. HOWELL; K. B. SCOTLAND; F. G. PEREZ; L. TORADO; L. C. FRANCESCONI, INORG. CHEM., vol. 43, 2004, pages 7691 |
| G. M. SHELDRICK, SADABS; PROGRAM FOR SCALING AND CORRECTION OF AREA DETECTOR DATA, 1997 |
| G. M. SHELDRICK, SHELX-TL VERSION 5.03, SOFTWARE PACKAGE FOR THE CRYSTAL STRUCTURE DETERMINATION, SIEMENS ANALYTICAL X-RAY INSTRUMENT DIVISION: MADISON, 1994 |
| H. EL MOLL ET AL., DALTON TRANS., vol. 41, 2012, pages 9955 |
| H. EL MOLL ET AL.: "polyoxometalales functionalized by bisphonate ligands: synthesis, structural, magnetic and spectroscopic characterizations and activity on tumor cell lines", INORG. CHEM., vol. 51, 2012, pages 7921 - 7931 |
| HANI EL MOLL ET AL., INORG. CHEM., vol. 51, 2012, pages 7921 - 7931 |
| HANI EL MOLL ET AL.: "polyoxometalates functionalized by bisphosphonate ligands: synthesis, structural, magnetic, and spectroscopic characterizations and activity on tumor cell lines", INORG. CHEM., vol. 51, 2012, pages 7921 - 7931, XP055225657, DOI: doi:10.1021/ic3010079 |
| HANI EL MOLL ET AL: "Polyoxometalates Functionalized by Bisphosphonate Ligands: Synthesis, Structural, Magnetic, and Spectroscopic Characterizations and Activity on Tumor Cell Lines", INORGANIC CHEMISTRY, vol. 51, no. 14, 16 July 2012 (2012-07-16), EASTON, US, pages 7921 - 7931, XP055225639, ISSN: 0020-1669, DOI: 10.1021/ic3010079 * |
| HUAQIAO TAN ET AL: "Two new cantilever-type polyoxometalates constructed from {Mo 2 O 4 } 2+ fragments and diphosphonates", DALTON TRANSACTIONS: THE INTERNATIONAL JOURNAL FOR INORGANIC, ORGANOMETALLIC AND BIOINORGANIC CHEMISTRY, vol. 39, no. 5, 1 January 2010 (2010-01-01), GB, pages 1245 - 1249, XP055229488, ISSN: 1477-9226, DOI: 10.1039/B912321K * |
| INORG. CHEM., vol. 51, 2012, pages 7921 - 7931 |
| JEAN DANIEL COMPAIN ET AL., CHEM EUR J., vol. 16, 2010, pages 13741 - 13748 |
| JEAN-DANIEL COMPAIN ET AL: "Tetra- to Dodecanuclear Oxomolybdate Complexes with Functionalized Bisphosphonate Ligands: Activity in Killing Tumor Cells", CHEMISTRY - A EUROPEAN JOURNAL., vol. 16, no. 46, 10 December 2010 (2010-12-10), WEINHEIM, DE, pages 13741 - 13748, XP055225664, ISSN: 0947-6539, DOI: 10.1002/chem.201001626 * |
| JINGYANG NIU ET AL., CHEM EUR. J., vol. 18, 2012, pages 6759 - 6762 |
| JINGYANG NIU ET AL: "Organodiphosphonate-Functionalized Lanthanopolyoxomolybdate Cages", CHEMISTRY - A EUROPEAN JOURNAL., vol. 18, no. 22, 29 May 2012 (2012-05-29), WEINHEIM, DE, pages 6759 - 6762, XP055225656, ISSN: 0947-6539, DOI: 10.1002/chem.201200974 * |
| KUBO, T.; SHIMOSE, S.; MATSUO, T.; TANAKA, K.; YASUNAGA, Y.; SAKAI, A.; OCHI, M., J. ORTHOP. RES., vol. 24, 2006, pages 1138 - 44 |
| L. YANG ET AL., CRYST. GROWTH. DES., vol. 13, 2013, pages 2540 |
| LIJUAN ZHANG ET AL: "A general synthesis approach in action: preparation and characterization of polyoxomolybdenum(vi) organophosphonates through oxidative Mo-Mo bond cleavage in {MoV2O4}", CRYSTENGCOMM, vol. 14, no. 14, 1 January 2012 (2012-01-01), pages 4826, XP055229493, DOI: 10.1039/c2ce25093d * |
| M. SADAKANE; M. H. DICKMAN; M. T. POPE, ANGEW. CHEM. INT. ED., vol. 39, 2000, pages 2914 |
| MILLER ET AL., FRONTIERS IN GENETICS, vol. 2, 2012, pages 1 - 9 |
| N. BELAI; M. T. POPE, CHEM. COMMUN., vol. 46, 2005, pages 5760 |
| R. BLESSING, ACTA CRYSTALLOGR, vol. A51, 1995, pages 33 |
| SAAD ALI ET AL: "Molybdenum Bisphosphonates with Cr(III) or Mn(III) Ions", JOURNAL OF CLUSTER SCIENCE, SPRINGER NEW YORK LLC, US, vol. 25, no. 3, 1 November 2013 (2013-11-01), pages 795 - 809, XP035335317, ISSN: 1040-7278, [retrieved on 20131101], DOI: 10.1007/S10876-013-0655-3 * |
| T. YUEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 11, 2014, pages 17989 |
| Y. LI; E.WANG ET AL.: "Two new cantilever-type polyoxometalates constructed from {Mo O }2+ fragments and diphosphonates", DALTON TRANS, vol. 39, 2010, pages 1245, XP055229488, DOI: doi:10.1039/B912321K |
| Y. XIA ET AL., SCI. TRANSL. MED., vol. 6, 2014, pages 263RA161 |
| Y. ZHANG ET AL., J. AM. CHEM. SOC., vol. 131, 2009, pages 5153 |
| Y. ZHANG, J. AM. CHEM. SOC., vol. 131, 2009, pages 51 |
| Y. ZHOU ET AL.: "A general synthesis approach in action: preparation and characterization of polyoxomolybdenum(VI) organophosphonates through oxidative Mo-Mo bond cleavage in {Mov O", CRYSTENG COMM, vol. 14, 2012, pages 4826, XP055229493, DOI: doi:10.1039/c2ce25093d |
| YIFENG XIA ET AL.: "a combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin", SCIENCETRANSLATIONMEDICINE, vol. 6, no. 263, 2014, pages 263RA161 |
| Z. ZHANG; Y. QI; C. QIN; Y. LI; E. WANG; X. WANG; Z. SU; L. XU, INORG. CHEM., vol. 46, 2007, pages 8162 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111886221A (en) * | 2018-03-16 | 2020-11-03 | 阿科玛法国公司 | Synthesis method of azo compound |
| CN111886221B (en) * | 2018-03-16 | 2023-06-02 | 阿科玛法国公司 | Synthesis method of azo compound |
| CN111138498A (en) * | 2019-12-27 | 2020-05-12 | 湖北工业大学 | Application of disubstituted aromatic acid modified Anderson polyacid as coxsackie virus inhibitor |
| CN111138498B (en) * | 2019-12-27 | 2022-10-04 | 湖北工业大学 | Application of disubstituted aromatic acid modified Anderson polyacid as coxsackie virus inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3098228A1 (en) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105899519B (en) | Metal complexes and methods of treatment | |
| Saad et al. | Polyoxomolybdate bisphosphonate heterometallic complexes: synthesis, structure, and activity on a breast cancer cell line | |
| CA2799771A1 (en) | Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients | |
| CN102731580B (en) | Binuclear platinum (II)-diphosphonic acid coordination compound, preparation method and application thereof | |
| Moghimi et al. | A ternary tetracoordinated PdII complex with metformin and dipicolinate: Synthesis, characterization and crystal structure | |
| AU2011314319B2 (en) | Metal complexes of N-heterocyclic carbenes | |
| WO2016189109A1 (en) | Polyoxomolybdate-bisphosphonate complex containing a heterometallic ion different from molybdenum | |
| US20080182834A1 (en) | Multi-Nuclear Metal Complexes Partially Encapsulated by Cucurbit[7-12]Urils | |
| AU2012364227B2 (en) | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment | |
| JP4162994B2 (en) | Compounds for use in the treatment of various disease states and methods for their preparation | |
| Liu et al. | New polyazamacrocyclic 3-hydroxy-4-pyridinone based ligands for iron depletion antitumor activity | |
| EP1043316B1 (en) | Nitroimidazole derivatives as sensitivity enhancers for chemotherapy and radiotherapy | |
| CN113698439B (en) | Lindqvist type heteropolyacid derivative and preparation method and application thereof | |
| KR101471498B1 (en) | Compounds and methods for the treatment of cancer | |
| WO2006138357A1 (en) | Macrocyclic metal complexes for their use as anticancer agents | |
| US8048870B2 (en) | Apoptosis-inducing antineoplastic silver (I) coordination complexes | |
| JP5919202B2 (en) | Medical carbon monoxide releasing rhenium compounds | |
| EP3564246B1 (en) | A gold(iii) complex, a conjugate of the gold(iii) complex, a pharmaceutical composition comprising the gold(iii) complex and uses and a process for preparing the gold(iii) complex | |
| EP1185540B1 (en) | Ruthenium dimeric complexes suitable as antimetastatic and antineoplastic agents | |
| WO2008076826A1 (en) | Pyrophosphoramide alkylators | |
| WO2013146437A1 (en) | 3-decenoic acid derivative and use for same | |
| JP4570833B2 (en) | Ruthenium (II) complex having antitumor activity and antimetastatic activity | |
| JP2006500383A (en) | Peroxynitrite transfer catalyst for treating or preventing diseases caused by peroxynitrite-mediated reactions | |
| Singh et al. | Antiproliferative activity of Fe (ii), Co (ii), Ni (ii), Cu (ii), and Zn (ii) complexes of dithiocarbamate: synthesis, structural characterization, and thermal studies | |
| AU2005204589A1 (en) | Multi-nuclear metal complexes partially encapsulated by Cucurbit[7-12]urils |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16725145 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 16725145 Country of ref document: EP Kind code of ref document: A1 |